<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-id journal-id-type="pmc-domain-id">2992</journal-id><journal-id journal-id-type="pmc-domain">heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10208947</article-id><article-id pub-id-type="pmcid-ver">PMC10208947.1</article-id><article-id pub-id-type="pmcaid">10208947</article-id><article-id pub-id-type="pmcaiid">10208947</article-id><article-id pub-id-type="pmid">37251909</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2023.e15991</article-id><article-id pub-id-type="pii">S2405-8440(23)03198-5</article-id><article-id pub-id-type="publisher-id">e15991</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>MicroRNA-372 acts as a double-edged sword in human cancers</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Tajik</surname><given-names initials="F">Fatemeh</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Alian</surname><given-names initials="F">Fatemeh</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Yousefi</surname><given-names initials="M">Mohammad</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Azadfallah</surname><given-names initials="A">Ali</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Hoseini</surname><given-names initials="A">Aref</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Mohammadi</surname><given-names initials="F">Forogh</given-names></name><email>F_mohammadi@iauksh.ac.ir</email><email>forogh_mo58@yahoo.com</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Karimi-Dehkordi</surname><given-names initials="M">Maryam</given-names></name><email>ma_karimivet58@yahoo.com</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor3" ref-type="corresp">&#8727;&#8727;&#8727;</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Alizadeh-Fanalou</surname><given-names initials="S">Shahin</given-names></name><email>alizadeh.sh@umsu.ac.ir</email><email>shahin.alizadeh60@yahoo.com</email><xref rid="aff6" ref-type="aff">f</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>b</label>Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran</aff><aff id="aff3"><label>c</label>Department of Medicine, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran</aff><aff id="aff4"><label>d</label>Department of Veterinary, Agriculture Faculty, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran</aff><aff id="aff5"><label>e</label>Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran</aff><aff id="aff6"><label>f</label>Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran</aff><aff id="aff7"><label>g</label>Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Nazlou Highway, Urmia University of Medical Sciences, Urmia, Iran. <email>alizadeh.sh@umsu.ac.ir</email><email>shahin.alizadeh60@yahoo.com</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author. <email>F_mohammadi@iauksh.ac.ir</email><email>forogh_mo58@yahoo.com</email></corresp><corresp id="cor3"><label>&#8727;&#8727;&#8727;</label>Corresponding author. <email>ma_karimivet58@yahoo.com</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Fatemeh Tajik and Fatemeh Alian equally contributed to the manuscript.</p></fn></author-notes><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>5</month><year>2023</year></pub-date><volume>9</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">434645</issue-id><elocation-id>e15991</elocation-id><history><date date-type="received"><day>9</day><month>12</month><year>2022</year></date><date date-type="rev-recd"><day>26</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-30 14:25:09.650"><day>30</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3&#8242;-UTR mRNAs and controlling gene expression at the post-transcriptional level. As an oncogene, miRNAs can either accelerate cancer progression or slow it down as a tumor suppressor. MicroRNA-372 (miR-372) has been found to have an abnormal expression in numerous human malignancies, implying that the miRNA plays a role in carcinogenesis. It is both increased and downregulated in various cancers, and it serves as both a tumor suppressor and an oncogene. This study examines the functions of miR-372 as well as the LncRNA/CircRNA-miRNA-mRNA signaling pathways in various malignancies and analyses its potential prognostic, diagnostic, and therapeutic implications.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>MicroRNA-372</kwd><kwd>Function</kwd><kwd>Importance</kwd><kwd>Cancer</kwd><kwd>Tumor suppressor</kwd><kwd>Oncogene</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Cancer is a complicated genetic disease that is the most rampant death in many nations after heart disease [<xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>]. It is estimated that approximately 28.4 million new cancer cases will be diagnosed in 2040, which will be drastically growing in comparison with the rate of cancer cases which was roughly 19.3 million in 2020 [<xref rid="bib4" ref-type="bibr">4</xref>]. Most rifle cancer among women is comprised of breast, lung, and colorectal cancer, while cancer, the most common among men, is such as prostate, lung, and bronchus cancer [<xref rid="bib2" ref-type="bibr">2</xref>]. Despite significant research on the diagnosis and treatment of cancer and its pain relief drugs, it remains the leading health concern [<xref rid="bib5" ref-type="bibr">5</xref>]. As a result, novel tumor-targeted therapies with greater efficiency and specificity are required. During the past few years, working on genes generating non-coding RNA (ncRNA) has been revolutionized in diagnosing and treating cancers [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. MicroRNAs are small (18&#8211;25 nucleotides), endogenous, single-stranded, ncRNAs expressed in cells to control gene expression at the post-transcription level through binding with the 3&#8217; untranslated region (3&#8217;-UTR) of target mRNA molecules [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>]. In addition, some studies demonstrated that miRs could bind to the 5&#8217; UTR of mRNAs to activate the translation of the target mRNA [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. MiRs, which were first discovered in 1993, has been proposed to play a critical role in various biological functions, comprising cell growth, apoptosis, migration, differentiation, and angiogenesis [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. Dysregulation of miRs is involved in many diseases, including cancer, cardiovascular disease, multiple sclerosis and diabetic nephropathy [<xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>]. The role of miRs in cancer was investigated for the first time in 2002 [<xref rid="bib20" ref-type="bibr">20</xref>]. They play the opposite role as either oncogenic miRs (oncomiRs) or tumor suppressors [<xref rid="bib21" ref-type="bibr">21</xref>]. OncomiRs are highly expressed in the cancer cells and enhance cancer cell division through decreased tumor suppressor genes, while tumor suppressor miRs regulate the processes of survival and cell cycle division [<xref rid="bib22" ref-type="bibr">22</xref>]. This discrimination depends on miR molecules' ability to intervene in carcinogenesis processes, comprising mechanisms associated with cell proliferation, invasion, metastasis, and apoptosis of cancer cells [<xref rid="bib21" ref-type="bibr">21</xref>]. The growing body of research on miRs and cancer is at an extraordinary rate. During the past few years, research on the association between miRs and cancer has drastically increased, and they can be used as prognostic or therapeutic markers in human cancers [<xref rid="bib23" ref-type="bibr">23</xref>].</p><p id="p0015">Over the past decade, research interest in the relationship between miRs and various malignancies has grown exponentially. The discovery of the potential of miRs in the prognosis, diagnosis, and treatment of human cancers has fueled this interest. Currently, miRs are being tightly investigated in various preclinical and clinical studies for their therapeutic potential in cancer treatment. These findings have the potential to lead to the development of new, more effective cancer treatments, and improve outcomes for cancer patients. Although there have been several studies that reviewed the role of various miRs in cancers, such as miR-1297 [<xref rid="bib24" ref-type="bibr">24</xref>], the dualistic role of miR-372 in cancer has not been evaluated. Therefore, for the first time, we aimed to review the role of miR-372 in various cancers comprehensively.</p><sec id="sec1.1"><label>1.1</label><title>miR-372</title><p id="p0020">MiRNA-372 (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) is a small ncRNA with one exosome count, located on the 19q13.42 chromosome [<xref rid="bib25" ref-type="bibr">25</xref>]. The function and expression pattern of miR-372 was first discovered in testicular germ cell tumors in 2006 [<xref rid="bib26" ref-type="bibr">26</xref>]. Since this miR was identified, several researchers have worked on its diverse function. Yasukawa et al. revealed that miR-372 can reduce the production of both IFN-&#946; and pro-inflammatory cytokines in response to viral infection and also controls MAVS-mediated antiviral innate immunity by regulating mitochondrial metabolism via the SLC25A12 transporter. They found that it could be a therapeutic antiviral target for the RNA viruses such as influenza A [<xref rid="bib27" ref-type="bibr">27</xref>]. Besides, Shan et al. acknowledged that miR-372 was upregulated in hyperlipidemic acute pancreatitis (HTGAP) and had a positive relationship with the severity of the disease. These findings could lead to an innovative strategy for diagnosing and assessing the severity of HTGAP [<xref rid="bib28" ref-type="bibr">28</xref>].<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The hairpin structure of pre-miR-372 and the sequence of mature miR-372-3p &amp; -5p. The miR-372 gene is transcribed into a precursor (pre-miR-372) with 66 nucleotides in the nucleus, transferred to the cytoplasm by Exportin-5 for further processing to yield mature miRNAs with 23 nucleotides for mature miR-372-3p &amp; -5p. The sequence of mature miR-372 is colored in red. The arrow indicates the orientations from 5&#8242; to 3&#8242;. The codes of miR-372 were extracted from miRBase.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0025">Furthermore, miR-372 increases primordial germ cell numbers by repressing multiple pathways, including cell cycle (CDKN1A, RBL2, CDC2L6), EMT (RHOC, TGFBR2), and epigenetic regulators (MECP2, SMARCC2) [<xref rid="bib29" ref-type="bibr">29</xref>]. Inhibiting these targets can also boost the formation of human-induced pluripotent stem cells [<xref rid="bib30" ref-type="bibr">30</xref>]. Dysregulation of miR-372 has been found in a distinct range of human tumors (such as breast cancer, colorectal cancer, hepatocellular carcinoma) [<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>]. The expression of microRNA in various cancers has two contrasting roles as either oncogenic or anti-oncogenic. In this review, we summarize the recent research results on the role of miR-372 in various human cancers and describe its potential diagnostic and therapeutic implications.</p></sec><sec id="sec1.2"><label>1.2</label><title>MiRNA-372 in cancerous diseases</title><p id="p0030">MiR-372 has been shown to play a crucial role in the carcinogenesis of a variety of human cancers, including Colorectal Cancer (CRC), Renal Cell Carcinoma (RCC), Lung Adenocarcinoma (LA), Hepatocellular Carcinoma (HCC), Gallbladder Carcinoma (GBC), Oral Cancer (OC), Cervical Cancer (CC), Testicular Germ Cell Tumor (TGCT), Pancreatic Adenocarcinoma (PAC), Gastric Cancer (GC), Cervical Cancer (CC), Ovarian Carcinoma (OVC), Breast Cancer (BC), Prostate Cancer (PC), Nasopharyngeal Carcinoma (NFC), Melanoma, Osteosarcoma (OS), and Glioma Cell (GLC). MiR-372 plays distinct roles in different malignancies, such as inhibiting or promoting proliferation, migration, invasion, epithelial&#8211;mesenchymal transition (EMT), induction or suppression of apoptosis, and cell-cycle arrest. Furthermore, its expression level in malignant tissues is commonly measured to be lower than in normal margin tissues, suggesting that miR-372 is a tumor suppressor. Since miR-372 behaves as an oncogene in some malignancies, its role as a tumor suppressor or oncogene in human neoplasms can be classified as cancer-type specific. MiR-372 induced both functionalities by targeting various genes, as detailed in <xref rid="tbl1" ref-type="table">Table 1</xref>. The action of Long non-coding RNAs (lncRNAs) or Circular RNAs (CircRNAs), which target miR-372s and operate as a competitive endogenous RNA (ceRNA), causes carcinogenesis in certain malignancies, the so-called sponge effect (<xref rid="tbl2" ref-type="table">Table 2</xref>). The interaction of miR-372 with its target genes, LncRNA and circRNA, and the results reported in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Target Genes of miRNA-372 Responsible for Its Tumor Suppressive/Oncogenic Action in Different Cancers.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">Location</th><th colspan="1" rowspan="1">Malignancy</th><th colspan="2" rowspan="1">Cell Lines</th><th colspan="1" rowspan="1">No. of Tissue sample</th><th colspan="1" rowspan="1">Outcomes</th><th colspan="1" rowspan="1">Protein</th><th colspan="1" rowspan="1">Mir- 372 expresstion</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">RUVBL2</td><td align="left" colspan="1" rowspan="1">19q13.3</td><td align="left" colspan="1" rowspan="1">Non-small cell lung cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CL 1-0</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Increases regulation of cell growth and transcription</td><td align="left" colspan="1" rowspan="1">RuvB-like 2</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib165" ref-type="bibr">165</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">BEAS-2B</td><td align="left" colspan="1" rowspan="1">A549</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Increases growth, migration, invasion and decreases apoptosis</td><td align="left" colspan="1" rowspan="1">Wnt/&#946;-catenin</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MTOR</td><td align="left" colspan="1" rowspan="1">1p36.2</td><td align="left" colspan="1" rowspan="1">Lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">BEAS-2B</td><td align="left" colspan="1" rowspan="1">A549</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Increases growth, migration, invasion and decreases apoptosis</td><td align="left" colspan="1" rowspan="1">mTOR</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CA12</td><td align="left" colspan="1" rowspan="1">15q22.2</td><td align="left" colspan="1" rowspan="1">Lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">A549</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Patients with reduced CA12 in tumors have an increased risk of recurrence</td><td align="left" colspan="1" rowspan="1">CA12 proteins</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib167" ref-type="bibr">167</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF9</td><td align="left" colspan="1" rowspan="1">13q12.11</td><td align="left" colspan="1" rowspan="1">Lung squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">BEAS-2B</td><td align="left" colspan="1" rowspan="1">NCI&#8211;H520,<break/>SK-MES-1 and NCI&#8211;H1703</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Induces cell cycle arrest in G0/G1 stage<break/>Increases apoptosis</td><td align="left" colspan="1" rowspan="1">FGF9</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib168" ref-type="bibr">168</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TP53</td><td align="left" colspan="1" rowspan="1">17p13.1</td><td align="left" colspan="1" rowspan="1">nasopharyngeal carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">5&#8211;8F,C666-1, TW01</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Enhancing radiosensitivity while suppressing invasion and metastasis</td><td align="left" colspan="1" rowspan="1">p53</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib169" ref-type="bibr">169</xref>,<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BAX</td><td align="left" colspan="1" rowspan="1">19q13.33</td><td align="left" colspan="1" rowspan="1">Nasopharyngeal Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">5&#8211;8F,C666-1,TW01</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Induces mitochondrial dysfunction and death</td><td align="left" colspan="1" rowspan="1">BAX</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib169" ref-type="bibr">169</xref>,<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCL2</td><td align="left" colspan="1" rowspan="1">18q21.33</td><td align="left" colspan="1" rowspan="1">Nasopharyngeal Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">5&#8211;8F,C666-1,TW01</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">inhibition of cell progression due to a prolong duration of G1 phase, anti-apoptotic gene</td><td align="left" colspan="1" rowspan="1">Bcl-2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib169" ref-type="bibr">169</xref>,<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CDK2</td><td align="left" colspan="1" rowspan="1">12q13.2</td><td align="left" colspan="1" rowspan="1">Nasopharyngeal Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">TW01</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cdk-2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CCNA1</td><td align="left" colspan="1" rowspan="1">13q13.3</td><td align="left" colspan="1" rowspan="1">Nasopharyngeal Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">TW01</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyclin-A1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PRKACB</td><td align="left" colspan="1" rowspan="1">1p31.1</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">QSG-7701, Chang liver and HL-7702</td><td align="left" colspan="1" rowspan="1">Huh-1<break/>Huh-4, Hep3B, HepG2, Huh-7, SNU-449, SNU-475</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Decreases phosphorylation of CREB and CERB down regulates HULC</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib171" ref-type="bibr">171</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ATAD2</td><td align="left" colspan="1" rowspan="1">8q24.13</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">LO2</td><td align="left" colspan="1" rowspan="1">SMMC7721, QGY-7701,<break/>Bel-7402, PLC5, Huh7, HCCLM3, HepG2</td><td align="left" colspan="1" rowspan="1">129</td><td align="left" colspan="1" rowspan="1">reduced their capacity for invasion and proliferation and led to a G1 phase arrest</td><td align="left" colspan="1" rowspan="1">tRNA-specific adenosine deaminase 2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib172" ref-type="bibr">172</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MCL-1</td><td align="left" colspan="1" rowspan="1">1q21.2</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">HepG2</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">Anti-apoptosis</td><td align="left" colspan="1" rowspan="1">Mcl-1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">E2F1</td><td align="left" colspan="1" rowspan="1">20q11.22</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">HUH-7/DDP</td><td align="left" colspan="1" rowspan="1">95</td><td align="left" colspan="1" rowspan="1">Anti-apoptosis</td><td align="left" colspan="1" rowspan="1">E2f-1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CUL4B</td><td align="left" colspan="1" rowspan="1">Chromosome X</td><td align="left" colspan="1" rowspan="1">Bladder cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">T24<break/>253J<break/>5637<break/>RT112<break/>RT4<break/>SV-HUC-1</td><td align="left" colspan="1" rowspan="1">77</td><td align="left" colspan="1" rowspan="1">Increased motility, invasiveness, stemness and chemoresistence</td><td align="left" colspan="1" rowspan="1">Cullin 4&#160;B</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib125" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FXYD</td><td align="left" colspan="1" rowspan="1">11q23.3</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">hfOB1.19</td><td align="left" colspan="1" rowspan="1">O2OS<break/>SOSP-9607<break/>MG-63</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Promotes tumor growth</td><td align="left" colspan="1" rowspan="1">FXYD6</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LATS2</td><td align="left" colspan="1" rowspan="1">13q12.11</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">OVCAR3<break/>A2780</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Large tumor suppressor kinase2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LATS2</td><td align="left" colspan="1" rowspan="1">13q12.11</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">DU145<break/>PC3</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">Tumor suppressor</td><td align="left" colspan="1" rowspan="1">Large tumor suppressor kinase2</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib150" ref-type="bibr">150</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LATS2</td><td align="left" colspan="1" rowspan="1">13q12.11</td><td align="left" colspan="1" rowspan="1">Testicular germ cell tumor</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Tumor suppressor</td><td align="left" colspan="1" rowspan="1">Large tumor suppressor kinase2</td><td align="left" colspan="1" rowspan="1">&#8593;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib26" ref-type="bibr">26</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">RhoC</td><td align="left" colspan="1" rowspan="1">1p13.2</td><td align="left" colspan="1" rowspan="1">Endometrial carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell growth<break/>Migration and invasion</td><td align="left" colspan="1" rowspan="1">RAS homolog family member C</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TP65</td><td align="left" colspan="1" rowspan="1">11q3</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">DU145</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Cell proliferation<break/>Invasion and migration</td><td align="left" colspan="1" rowspan="1">P65</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib149" ref-type="bibr">149</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Sequestosome 1</td><td align="left" colspan="1" rowspan="1">5q35.3</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">OVCAR3<break/>A2780</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">P62</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CDK2</td><td align="left" colspan="1" rowspan="1">12q13.2</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">HeLa<break/>C33A</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyciln-dependent kinase 2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CDK2</td><td align="left" colspan="1" rowspan="1">12q13.2</td><td align="left" colspan="1" rowspan="1">Endometrial cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyciln-dependent kinase 2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CCNA1</td><td align="left" colspan="1" rowspan="1">13q13.3</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">HeLa<break/>C33A</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyclin A1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CCNA1</td><td align="left" colspan="1" rowspan="1">13q13.3</td><td align="left" colspan="1" rowspan="1">Endometrial caner</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyclin A1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CCNA1</td><td align="left" colspan="1" rowspan="1">13q13.3</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">OVCAR3<break/>A2780</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Cyclin A1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ATAD2</td><td align="left" colspan="1" rowspan="1">8q24</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">OVCAR3<break/>A2780</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation and metastasis</td><td align="left" colspan="1" rowspan="1">ATPase Family AAA Domain Containing 2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ATAD2</td><td align="left" colspan="1" rowspan="1">8.q24</td><td align="left" colspan="1" rowspan="1">Renal cell carcinoma</td><td align="left" colspan="1" rowspan="1">HK2</td><td align="left" colspan="1" rowspan="1">Caki-1<break/>786-O<break/>A498<break/>ACHN<break/>Caki-2</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">ATPase Family AAA Domain Containing 2</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DKK1</td><td align="left" colspan="1" rowspan="1">10q21.1</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">OVCAR3<break/>A2780</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Cell proliferation</td><td align="left" colspan="1" rowspan="1">Dickkopf-related protein 1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">IGF2BP1</td><td align="left" colspan="1" rowspan="1">17q21.32</td><td align="left" colspan="1" rowspan="1">Renal cell carcinoma</td><td align="left" colspan="1" rowspan="1">HK2</td><td align="left" colspan="1" rowspan="1">769-P<break/>786-O<break/>A498<break/>SN12-PM6</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Cell proliferation and invasion</td><td align="left" colspan="1" rowspan="1">Insulin-like growth factor2 mRNA-binding protein1</td><td align="left" colspan="1" rowspan="1">&#8595;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib142" ref-type="bibr">142</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>N/A: Not Applicable.</p></fn><fn id="tspara0020"><p>&#8593;: Increased expression of miR-372.</p></fn><fn id="tspara0025"><p>&#8595;: Decreased expression of miR-372.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Oncogenic Circular RNA and Long Non-Coding RNAs (lncRNA), Which Act as Competitive Endogenous RNA (ceRNA) for miR-372 (So-Called Sponging Effect) in Different Cancers.</p></caption><alt-text id="alttext0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">RNA</th><th rowspan="2" colspan="1">Malignancy</th><th colspan="2" rowspan="1">Cell Lines<hr/></th><th rowspan="2" colspan="1">No. of Tissue Samples (Pair)</th><th rowspan="2" colspan="1">Outcomes</th><th rowspan="2" colspan="1">References</th></tr><tr><th colspan="1" rowspan="1">Normal</th><th colspan="1" rowspan="1">Cancerous</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">KCNQ1OT1</td><td align="left" colspan="1" rowspan="1">Lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">HEK293</td><td align="left" colspan="1" rowspan="1">A549,<break/>H1975</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">larger tumor, advanced clinical stage, and a lower response rate to concurrent therapy</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib175" ref-type="bibr">175</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OSER1-AS1</td><td align="left" colspan="1" rowspan="1">Hepatocellular Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">HepG2 and Hep3b</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">the proliferation, invasion and migration of HCC cells, and induced the<break/>apoptosis</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib176" ref-type="bibr">176</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LncRNA HULC</td><td align="left" colspan="1" rowspan="1">Hepatocellular Carcinoma</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">tumor node and metastases (TNM) higer stage,<break/>HCC recurrence, intra-hepatic metastases, and Lower postoperative survival.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib62" ref-type="bibr">[62]</xref>, <xref rid="bib171" ref-type="bibr">[171]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PCAT-14</td><td align="left" colspan="1" rowspan="1">Hepatocellular Carcinoma</td><td align="left" colspan="1" rowspan="1">LO2</td><td align="left" colspan="1" rowspan="1">Huh7,<break/>HCCLM3, HepG2, SMMC7721, PLC5, and QGY7701</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">proliferation and invasion of hepatocellular carcinoma cells</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LncRNA HULC</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">HfoB</td><td align="left" colspan="1" rowspan="1">SAOS-2<break/>U2OS<break/>HoS<break/>MG63</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">Cell proliferation, migration and invasion of OS cells</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib119" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Circ_0001721</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">HfoB1.19</td><td align="left" colspan="1" rowspan="1">U2OS<break/>HoS</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">Tumor growth, proliferation, invasion, migration, EMT and promote cell apoptosis</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib118" ref-type="bibr">118</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>N/A: Not Applicable.</p></fn></table-wrap-foot></table-wrap><fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Effects of miR-372 on its target genes for regulating tumorigenesis biological behaviors. In the figure, all the target genes of miR-372 with tumorigenesis of human cancers have been shown. For example, miR-372 represses tumorigenesis by suppressing the PRKAC8 gene. In this regard, lncRNA-HULC inhibits the anti-tumor effect of miR-372. On the other hand, it has been reported that miR-372 via suppressing the FGF9 as well as activation of Wnt/B-Catenin and mtor signaling pathway leads to increased tumorigenesis biological behaviors.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec1.3"><label>1.3</label><title>MiRNA-372 and nervous system cancers</title><p id="p0035">Central nervous system (CNS) tumors involve mainly the brain (&gt;90%) and the lesser other parts of the CNS. Malignancies that spread rapidly develop robust angiogenesis, invade normal brain tissue, reveal a short median survival time, and subsequently have a poor prognosis [<xref rid="bib24" ref-type="bibr">24</xref>]. The globocan 2020 database provides the latest global data on cancer burden cancer deaths. Its result revealed brain and other nervous system accounts for 1.6% of new cases of all cancer site (19292789 all sites) and 2.5% of new deaths in all cancer site of new deaths 9958133 all deaths [<xref rid="bib4" ref-type="bibr">4</xref>].</p><p id="p0040">Glioma is one of the lethal types of brain tumor originating from the glial cell. The glial cell consists of astrocyte oligodendrocyte and ependymal cells. Gliomas account for approximately 50% of all malignant primary brain tumors in adults. According to tumor growth potential and aggressiveness, WHO classified 4 grades for glioma that 1,2 grade is low, and 3,4 are high. Surgery, radiation therapy, and chemotherapy are treatments that take the situation of the patient into account, although, despite these treatments, the short median survival time is just approximately 14.6 months [<xref rid="bib24" ref-type="bibr">24</xref>].</p><p id="p0045">Understanding the disease's pathogenesis to develop new therapeutic and diagnostic strategies for glioma is crucial. miRNAs are a class of non-coding RNA that influence various physiological and pathological processes like differentiation, proliferation, apoptosis, and invasion by regulating the expression of genes at the post-transcriptional level. The profiling of miRNA in gliomas has been studied in several studies, and a series of miRNA, including mir-9, miR-17, miR-21, miR-184, and miR-342-3p, be predictive biomarkers associated with glioma progression and clinical outcome. There is also evidence that miR-26a, miR100, miR155, and miR &#8722;218 are both tumor suppressors and oncogenes in glioma [<xref rid="bib34" ref-type="bibr">34</xref>].</p><p id="p0050">Even so, far better therapeutic opportunities for glioma patients and more insight into the molecular mechanisms of glioma miRNAs are needed. miR-372 is one of the members of miRNAs that the latest evidence has shown. It has a tumor-suppressing role in glioma. This review focuses on different mechanisms of miR-372 activity in glioma cells.</p><p id="p0055">A study has proved that the expression of miR-372 was higher in glioma tissue compared to normal brain tissue. The high miR-372 expression was associated with the advanced pathological grade of the patient. Chen et al. assessment unveiled that downregulation of miR-372 considerably inhibited cell proliferation by modulating PHLPP2. They transfected cells with miR-372 inhibitor, and analysis showed that inhibition of miR-372 increased the level of PHLPP2 mRNA and protein expression, thus inhibiting the PI3K/AKT signaling pathway. In other words, inhibition of miR-372 led to a decrease in the phosphorylation levels of critical components of the PI3K/Akt pathway, such as Akt, mechanistic target of rapamycin (mTOR), and P70S6K, suggesting that miR-372 may be an important regulator of PI3K/Akt pathway in glioma tissues. Also, luciferase reporter assay results showed that luciferase activity of cells transfected with miR-372 inhibitor was significantly increased. Furthermore, PHLPP2 has been shown to induce apoptosis and limit tumor growth in glioblastoma cell lines [<xref rid="bib34" ref-type="bibr">34</xref>].</p><p id="p0060">Recent research indicates that long noncoding RNAs are key regulatory factors in cancers. FER1L4, one of the important members of LnRNA investigated in the literature, regulates the cell progression in G2-M through regulating E2F transcription factor 1 (E2F1). Xia et al. found that FER1L4 and E2F1 were highly expressed in grade 4 glioma tissues. Also, their expression significantly differs between grade &#8546; glioma tissues and grade &#8545;. Thus, FER1L4 and E2F1 overexpression predict poor prognosis of gliomas, and FER1L4 knocking down can inhibit the proliferation and cell progression of glioma cells. This study proved that overexpression of hsa-miR-372 caused the downregulation of both FER1L4 and E2F1 expression, and it has a remarkably negative effect on glioma cell proliferation [<xref rid="bib35" ref-type="bibr">35</xref>].</p><p id="p0065">One of the dangerous side effects of vascular surgeries and thoracic surgeries is spinal cord ischemia/reperfusion injury (SCII). The pathological effect of SCII is nerve cell apoptosis which causes limb movement and sensory dysfunction. In-vivo and in-vitro examinations conducted by Moradi et al. unveiled that in spinal cord tissue of SCII rats, expression of miR-34a considerably increased. Also, they observed that miR-372 knocking down caused upregulation of becline-1 as a regulator of autophagy and subsequently reduced spinal cord neurons apoptosis [<xref rid="bib36" ref-type="bibr">36</xref>].</p><p id="p0070">One of the most prevalent neoplasms worldwide is head and neck squamous cell carcinoma (HNSCC); hypoxia occurs during most tumors&#8217; late stage. Under hypoxic conditions, specific transcription factors, including hypoxia-inducible factors (HIFs), control transcription programs that promote cell survival in an adverse microenvironment. As a result of Yeh et al. observation of head and neck tumors in late stages. Hypoxia upregulates HIF-1&#945; in head and neck keratinocytes. Then HIF-1&#945; upregulate miR372. They identified that miR-372 could stimulate migration and increase ROS by targeting p62 through binding to its 3'-UTR site and causing downregulation of p62 (also called sequestosome1 or SQSTM1 is a ubiquitin-binding protein). Eventually, this study elucidates those high levels of plasma and salivary miR-372 corresponded to the progression of HNSCC and higher mortality of the patient [<xref rid="bib37" ref-type="bibr">37</xref>].</p><p id="p0075">The contradictory expression pattern of miR-372 in different tissue is what a thing makes this field interesting, and it needs more research for therapeutic and prognostic purposes.</p></sec><sec id="sec1.4"><label>1.4</label><title>MiRNA-372 and respiratory system cancers</title><p id="p0080">Lung carcinoma has progressed from an uncommon disease to one of the most common cancers globally and a leading cause of death from cancer in the last century [<xref rid="bib38" ref-type="bibr">38</xref>]. Furthermore, a global statistical analysis demonstrated that 1.8 million new cases were diagnosed worldwide in 2012 [<xref rid="bib39" ref-type="bibr">39</xref>]. Lung cancer risk factors include genetic and behavioral factors, chronic inflammation from infections, ionizing radiation, air pollution, and other risk factors [<xref rid="bib40" ref-type="bibr">40</xref>]. It is becoming increasingly difficult to ignore the low overall 5-year survival rate for lung cancer and its minimally changes in decades [<xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>]. Thus, several attempts have been made to recommend possible therapeutic targets. In 2012, Lai et al. reported that miR-372 increased the invasive ability of CL 1&#8211;0, and comparative proteomic profiling was used to identify the possible mechanism. Findings of the study showed that the possible mechanism is a complement of the RNA sequence of miR-372 with ribonucleic acid sequences of eukaryotic initiation factor 4A-I, heat shock protein 90-alpha, and RuvB-like 2 [<xref rid="bib44" ref-type="bibr">44</xref>]. Three years later, Mallick et al. suggested that cells with overexpression of MiR-372 proliferated faster with a higher percentage of the cells in the S phase of the cell cycle and had more capability for migrating and invading the extracellular matrix. Also, these cells formed bigger xenograft tumors in mice, and microarray analysis demonstrated that overexpression of MiR-372 altered the expression of 1,186 genes. One of the critical genes investigated in this study was the anhydrase-encoding CA12 gene which downregulation of this gene by MiR-372 plays a crucial role in the risk of cancer recurrence. Finally, they concluded that a higher miR-372 level correlates with a poorer prognosis in NSCLC [<xref rid="bib45" ref-type="bibr">45</xref>]. In 2017, Wang et al. <italic toggle="yes">trans</italic>-infected lung squamous cell carcinoma (LSCC) with Mir-372-3p, which led to suppression of Fibroblast Growth Factor 9 (FGF9) expression. Thus, Mir-372-p has an oncogenic effect by promoting cell growth and metastasis via targeting FGF9 [<xref rid="bib46" ref-type="bibr">46</xref>].</p><p id="p0085">Furthermore, in 2018 Sun et al. demonstrated that in comparison to the propofol&#160;+&#160;negative control group, the expression levels of Wnt3a, p/total &#946;-catenin, p/total p70S6K, and p/total mTOR proteins in human lung cancer cells were increased in the propofol&#160;+&#160;miR-372 mimic group and decreased in the propofol&#160;+&#160;miR-372 inhibitor group. These results indicate that propofol suppressed growth, migration, and invasion of lung adenocarcinoma cells and inactivation of Wnt/&#946;-catenin and mTOR pathways by down-regulation of miR-372 [<xref rid="bib47" ref-type="bibr">47</xref>].</p><p id="p0090">A recently published paper by Moradi et al. investigated possible causes of resistance to stereotactic body radiotherapy in the lung. This study detected downstream miRNA expression and upregulated miR-372-3p after sh-KCNQ1OT1 transfection by microarray. The possible mechanism of KCNQ1OT1-induced SBRT resistance mentioned in the promotion of ATG5-and ATG12-dependent autophagy via sponging miR-372-3p. In addition, overexpression of miR-372-3p inhibited autophagy and enhanced the radiosensitivity of IR-resistant cells [<xref rid="bib48" ref-type="bibr">48</xref>].</p><p id="p0095">Nasopharyngeal carcinoma (NPC) is a rare malignancy worldwide, but it is endemic in some geographical regions, including Southeast Asia, North Africa, and the Arctic [<xref rid="bib49" ref-type="bibr">49</xref>]. Also, epidemiological trends have shown that its incidence has declined gradually in the past decade [<xref rid="bib50" ref-type="bibr">50</xref>] The main risk factors of NPC include Epstein-Barr virus infection, high consumption of salt-preserved fish, smoking, and lack of fresh fruit and vegetable intake [<xref rid="bib51" ref-type="bibr">51</xref>] However, the major problem with NPC is that &gt;70% of patients were diagnosed at advanced stages, and the median survival of these patients is three years. Thus, improving diagnostic and therapeutic methods is necessary [<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib53" ref-type="bibr">53</xref>]. Meanwhile, microRNAs have been reported to regulate tumor radio-sensitivity by modulating DNA damage repair, cell cycle checkpoint, tumor microenvironment, and apoptosis [<xref rid="bib54" ref-type="bibr">54</xref>]. Therefore, several studies have been conducted to identify the role of mir-372 on radiosensitivity, invasion, and metastasis of NPC. In 2014, Tan et al. transfected NPC TW01&#160;cells with the miR-372 precursor molecules and conducted gene expression studies using RT-PCR assays for nine cancer-related genes. Furthermore, they investigated the effects of miR-372 on cell proliferation, cell cycle arrest, and apoptosis. Findings demonstrated that a "high level of MiR-372 resulted in a significant increase of cells at the S phase and reduced cells in both the G2/M phase". Also, a comparison between transfected TW01&#160;cells and untransfected cells revealed that four genes, including INCA1, CDKN1A, BIRC5, and LATS2, were up-regulated, and five genes including CCNA1, CDK2, BAX, TP53, and BCL2 were down-regulated in the transfected TW01&#160;cells. The possible mechanism for decreasing TW01&#160;cell proliferation and S phase cell arrest is down-regulating both CDK2 and CCNA1 by directly binding to their 3'UTR regions [<xref rid="bib55" ref-type="bibr">55</xref>]. In 2018, Wang, Z. et al. studied the role of miR&#8208;372 in radio-sensitivity, invasion, and metastasis of NPC by using microarray analysis to explore NPC&#8208;related differentially expressed genes. They also investigated the PBK&#8208;dependent p53 signaling pathway. Findings demonstrated that miR&#8208;372 expression enhanced radiosensitivity while suppressing invasion and metastasis via the expression of PBK and activating the p53 signaling pathway. Besides, over&#8208;expressed miR&#8208;372 down&#8208;regulated PKB and Bcl&#8208;2 expression and the extent of Akt phosphorylation while up&#8208;regulated the expression of Bax and p53 [<xref rid="bib56" ref-type="bibr">56</xref>]. Surprisingly, we found that miR-372 plays an anti-tumor role in NPC, unlike its oncogenic role in lung carcinoma. These findings may suggest novel ideas for future NPC treatments. Overall, our study shows that mir-372 plays an oncogenic role in different types of lung cancer, which would be a potential therapeutic target to improve lung cancer treatments.</p></sec><sec id="sec1.5"><label>1.5</label><title>MiRNA-372 and hepatocellular carcinoma</title><p id="p0100">Primary liver cancer is the fifth most common cancer and the third cause of death among different cancers worldwide [<xref rid="bib57" ref-type="bibr">57</xref>]. Furthermore, the incidence of liver cancer is becoming a warning state, with 841,080 cases globally [<xref rid="bib58" ref-type="bibr">58</xref>]. Several studies were accomplished to illuminate molecular pathways involving primary liver cancer. In this regard, Wu et al. found the anti-tumor role of MiR-372 in hepatocellular carcinoma (HCC) via four experimental shreds of evidence, including (a) downregulation of MiR-372 in HCC cells; (b) aberrantly high DNA methylation of gene promoter in the MiR-372 that induces epigenetic silencing of MiR-372; (c) MiR-372 can inhibit proliferation and invasion of HCC cell lines; (d) low Mir-372 was related with tumor metastasis and poor prognosis [<xref rid="bib59" ref-type="bibr">59</xref>]. These findings contradict a previous study accomplished by Gu et al., demonstrating that the expression of miR-372 in HCC is higher than in normal cells and correlates with advanced tumor progression [<xref rid="bib33" ref-type="bibr">33</xref>]. However, more recent evidence supported the anti-tumor role of miR-372 in HCC [<xref rid="bib60" ref-type="bibr">[60]</xref>, <xref rid="bib61" ref-type="bibr">[61]</xref>, <xref rid="bib62" ref-type="bibr">[62]</xref>]. In 2020 Soliman et al. published a paper that described that over-expression of MiR-372-p in HepG2 indirectly reduced the expression of Mcl-1(myeloid cell leukemia 1) at both gene and protein levels. Mcl-1 is a key anti-apoptotic protein member of the Bcl-2 family and is identified to have an important role in tumor pathogenesis [<xref rid="bib60" ref-type="bibr">60</xref>]. Furthermore, in 2019 Fan et al. expressed that MiR-372-3p was under-expressed in HCC tissues and negatively correlated with the level of OSER1-AS1. OSER1-AS1 is a long non-coding RNA (lncRNA) that might play an oncogenic role in HCC, and the high expression of OSER1-AS1 was closely associated with advanced tumor stages, larger tumor size, and lower disease survival in HCC patients. The possible mechanism is a molecular sponge role of OSER1-AS1 for miR-372-3p to promote Rab23 expression [<xref rid="bib61" ref-type="bibr">61</xref>]. Previous studies support this claim that higher expression of Rab23 was detected in HCC and was related to the poor overall survival of patients [<xref rid="bib63" ref-type="bibr">63</xref>,<xref rid="bib64" ref-type="bibr">64</xref>]. LncRNA, highly up-regulated in liver cancer (HULC), is another Competitive Endogenous RNA (ceRNA) for miR-372 investigated by Wang et al. nine years before. This study demonstrated that inhibition of miR-372 reduces translational repression of its target gene, PRKACB, which in turn induces phosphorylation of CREB (cAMP response element binding protein). CERB up-regulates the HULC expression level, which in turn starts a cascade of molecular events to increase the chromatin accessibility for the general transcription in liver HCC [<xref rid="bib65" ref-type="bibr">65</xref>]. In 2020 Shaker et al. also reported the inhibitory role of HULC for MiR-372 and lower expression levels of MiR-372 in both HCC and HCV groups compared to the control group [<xref rid="bib62" ref-type="bibr">62</xref>]. PCAT-14 is another lncRNA that inhibits miR-372 expression by inducing methylation of CpG islands in the miR-372 promoter. Inhibition of MiR-372 promotes the ATAD2 gene and Hedgehog (Hh) pathway key proteins, including PTCH-1, SMO, and Gli2. Finally, the Hh pathway induces proliferation, invasion, and cell cycle in HCC cells [<xref rid="bib66" ref-type="bibr">66</xref>]. Another study also confirmed that the ATAD2 mRNA 3&#8242; non-coding region (3&#8242; UTR) has a binding site for miR-372 and ATAD2 knockdown, decreasing liver cancer cells' invasive and migratory capacity. Also, this study mentioned the up-regulated APC gene and downregulated CTNNA1 gene after knocking down ATAD2, so concluded it might be the mechanism of ATAD2 gene action [<xref rid="bib67" ref-type="bibr">67</xref>]. In 2021, Wang et al. investigated the potential role of Fer-1 like family member 4 (FER1L4) in chemotherapy resistance and liver cancer development. They applied dual-luciferase reporter gene assay, bioinformatics analysis, and RNA pull-down were to compare possible binding relationships between clinically collected liver cancer tissues and the HUH-7/DDP cell line. Results demonstrated that FER1L4 promotes drug-resistant liver cancer progression by inhibiting miR-106a and miR- 372-5p expression. MiR-106a and miR- 372-5p knock-down results to upregulation of E2F1 and activation of nuclear factor-&#954;B (NF-&#954;B). NF-kB up-regulates Bcl-2, PCNA, MMP9, and P50, which inhibits apoptosis pathway. Therefore, suppression of NF-&#954;B may be new therapeutic target for the drug-resistant HCC treatment [<xref rid="bib68" ref-type="bibr">68</xref>]. Altogether, our study provides evidence that miR-372 plays an anti-tumor role in HCC. These findings may shed light on the improvement of HCC treatments.</p></sec><sec id="sec1.6"><label>1.6</label><title>MiRNA-372 and gastrointestinal cancers</title><p id="p0105">The prevalent head and neck carcinoma are oral cavity cancers whose death rate is exponentially high despite improving diagnosis. The five-year survival of this disease is about 50%. As a result, detecting biomarker plays a staple role in the early diagnosis of such cancer. One of the biomarkers worked over the past decade is the micro-RNA form of tumor genesis and tumor suppressor [<xref rid="bib69" ref-type="bibr">69</xref>]. In what follows, the impact of miR-372 on oral cancer worked by some investigators is reviewed. The commonality between the outcome of these studies was upregulating miR-372 in oral squamous cell carcinoma (OSCC). Yeh et al. (2018) asserted that the target gene of miR-372 is Zinc finger and BTB domain-containing 7A (ZBTB7A), which is inversely related to miR-372. ZBTB7A expression augments drug (CDDP) sensitivity through activating three death receptors named Trail-R1, Trail-R2, and Fans expression [<xref rid="bib70" ref-type="bibr">70</xref>]. In addition to mentioned issues, Yeh et al. (2020) underlined that ZBTB7A can <italic toggle="yes">trans</italic>-activate merely TRAIL-R2. Besides, they declined in ZBTB7A expression, leading to aggravating prognosis and boosting the migration of OSCC cells, proliferation cells in the G2/M stage, and invasion of tumor cells [<xref rid="bib71" ref-type="bibr">71</xref>]. Yeh et al. (2014) reported that hypoxia is conducive to the overexpression of miR-372, which is associated with the development of OSCC. This study identified a new target of miR-372 named P62, upsetting ROS equilibrium and leading to decreasing migration of tumor cells [<xref rid="bib72" ref-type="bibr">72</xref>]. Some scholars emphasized that nodal metastasis, lympho-vascular invasion, and poor survival correlated with the high level of miR-372 [<xref rid="bib73" ref-type="bibr">73</xref>,<xref rid="bib74" ref-type="bibr">74</xref>]. Plus, Tu et al. emphasize that LATS2 expression, the target gene of miR-372, is negatively related to miR-372 [<xref rid="bib73" ref-type="bibr">73</xref>]. Furthermore, another study maintained that mono-2-ethyhexyl phthalate (MEHP) contributed to aggrandizing oral cancer cells and proliferating cell nuclear antigens (PCNA). However, it lowers miR-372-5p expression. In fact, the target of miR-372-5p is PCNA (3&#8217;UTR domain) which is inversely associated with miR-372-5p [<xref rid="bib75" ref-type="bibr">75</xref>].</p><p id="p0110">Gastric Cancer (GC) is the fifth most diagnosed cancer and the fourth most common cause of cancer death. In 2020, approximately 769,000 out of over one million died from stomach cancer worldwide. Research shows that the incidence rate among men is two times higher than women. GCs can be fundamentally divided into two main categories consisting of cardia (CGC) and non-cardia (NCGC) [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib76" ref-type="bibr">76</xref>]. The risk factors for gastric cancer are helicobacter pylori infection, low socioeconomic status, tobacco smoking, alcohol consumption, diet, and genetic factors [<xref rid="bib77" ref-type="bibr">77</xref>,<xref rid="bib78" ref-type="bibr">78</xref>]. In 2006, the connection between microRNA and GC was firstly identified, which could play an essential role in the early detection of gastric cancer [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>]. Evidence from disparate research shows a high correlation between Gastric cancers and overexpression of miR-372, whose role is oncogenicity.</p><p id="p0115">According to Cho et al. and Ghasemi et al., LATS2, the target of miR-372, is negatively associated with miR-372. Either overexpression of LATS2 or the inhibition of miR-372 by AS-miR-372 use leads to lowering the proliferation of tumor cells, ceasing the cell cycle at the stage of G2M, and boosting AGS cells apoptosis [<xref rid="bib81" ref-type="bibr">81</xref>,<xref rid="bib82" ref-type="bibr">82</xref>]. Besides, Cho et al. suggested that the increased level of LAST2 is conducive to reducing Cyclin B, Cds2, Bcl, and ICAD expression and increasing AGS cell apoptosis [<xref rid="bib81" ref-type="bibr">81</xref>]. Furthermore, as reported by Ghasemi et al., the decrease of LATS2 brings about the unsteadiness of the genome throughout cell division and making micronuclei [<xref rid="bib82" ref-type="bibr">82</xref>]. In the other study reported by Zhou et al., miR-372 is attached to the 3'UTR site of tumor necrosis factor &#945;-induced protein 1 (TNFAIP1), which is inversely associated with miR-372 expression; MiR-372 leads to the development of tumor cells and the inhibition of apoptosis. Moreover, they professed that TNFAIP1 acts as a mediator between miR-372 and NF&#954;B activation, resulting in enhanced cell survival through the activation of anti-apoptotic genes downstream of NF&#954;B. Collectively, our data indicate that an oncogenic role of miR-372 may be through control of cell growth and cell apoptosis by downregulating the TNFAIP1 and positively regulating NF&#954;B expression.</p><p id="p0120">Plus, they asserted that miR-372 expression is unmeasurable, as well as the high level of TNFAIP1 in the HGS cell line, but the level of miR-372 is high in the AGS cell line [<xref rid="bib83" ref-type="bibr">83</xref>]. Staedel et al. evaluated the effect of 8-<italic toggle="yes">mer</italic>-locked nucleic acid (LNA) on miR-372 seeds leading to the inhibition of miR-372 and the increase of LAST2, which is a target of miR-372 expression. All mentioned factors contribute to reducing the growth of cells [<xref rid="bib84" ref-type="bibr">84</xref>]. Following one research investigation conducted by Belair et al., after approximately 24&#160;h of the helicobacter pylori, infection causes the miR-372 expression to lower and LAST2 to augment. In a sense, the mentioned process is conducive to terminating the cell cycle at the phase of the G1/S. This downregulation of miR-372 expression relies on the place of bacteria effector cog-A getting attached to the host cells. The augmentation of miR-372 expression may contribute to the proliferation of the cell cycle throughout the increased level of p21cip1/waf1, which fundamentally builds up in AGS cells [<xref rid="bib85" ref-type="bibr">85</xref>]. Vo et al. came up with the innovative idea, which is new small RNA ligands including two RNA binding motives conjugation. Small RNA precludes the synthesis of tumorigenesis miR-372 by inhibiting the Dicer enzymes process playing a role in constructing miRNA, which is made of pre-miRNAs. Moreover, they asserted that the target of this miRNA is the LATS-2 protein [<xref rid="bib86" ref-type="bibr">86</xref>].</p><p id="p0125">The third most prevalent cancer, diagnosed in women and men, is called CRC, divided into the colon, rectal and anal cancers. The evidence of many kinds of research acknowledges that CRCs will have grown drastically among the vast majority of older people by 2035 [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib76" ref-type="bibr">76</xref>]. With regard to the high prevalence and importance of CRC, different dimensions of pathogenesis have been taken into account at a molecular level in recent years [<xref rid="bib87" ref-type="bibr">87</xref>,<xref rid="bib88" ref-type="bibr">88</xref>]. Many researchers have analyzed the relationship between microRNA-372 and colorectal cancer during the past few years. A growing body of evidence indicates that those patients diagnosed with CRC fundamentally have high expression of microRNA-372 in their body, act as a carcinogen and play an essential role in tumorigenesis in CRC [<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib89" ref-type="bibr">[89]</xref>, <xref rid="bib90" ref-type="bibr">[90]</xref>, <xref rid="bib91" ref-type="bibr">[91]</xref>, <xref rid="bib92" ref-type="bibr">[92]</xref>, <xref rid="bib93" ref-type="bibr">[93]</xref>]. According to Yamashito&#8217;s research outcome, a target of miR-372 is a large tumor suppressor 2 (LATS2), which is inversely correlated with miR-372.</p><p id="p0130">Furthermore, they asserted that upregulation of miR-372 has a fundamental relationship with distant metastasis, particularly in, Liver. In a sense, those patients diagnosed with liver metastasis have drastically higher expression of miR-372 and lower expression of LAST2 than other patients without liver metastasis. Besides, Yamashito&#8217;s research found that patients with high miR-372 expression are exposed to shorter five-year survival rates and are considered a poor prognosis factor [<xref rid="bib32" ref-type="bibr">32</xref>]. Peng et al. obtained the same outcome showing LATS2 is a target of miR-372-3p, which had an inverse correlation with LATS2. The high expression of miR-372-3p is closely tied up with tumor size and differentiation of CRC cells, and it pertains to the lowest five-year relative survival. The role of LATS2 is to suppress tumor genes, mitigating the proliferation, migration, and apoptosis of CRC cells through a Hippo signaling pathway [<xref rid="bib89" ref-type="bibr">89</xref>]. Based on Yu&#8217;s and his colleagues&#8217; research, the level of miR-372 remarkably upgraded both CRC and colon precancerous lesions (CPL). The increased level of miR-372 expression is related to tumor size, Tumor-Nodes-Metastasis (TNM) stage, leading to worse overall survival. The serum levels of miR-372 drastically decreased in those ECRC patients undergoing surgery relative to preoperative serum miR-372 levels. Taken together, the serum levels of miR-372 are of significant importance in the early diagnosis and prognosis of CRC [<xref rid="bib90" ref-type="bibr">90</xref>]. According to Zhang et al., miR-372 is the predictor factor for the response to chemotherapy in patients with CRC [<xref rid="bib91" ref-type="bibr">91</xref>]. Ragusa et al. contended that the miR-372 is higher in CRC patients with mutated KRAS than those with wild-type genotype. They introduced another signaling pathway called mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), which regulates miR-372 through TRBP phosphorylation. The outcome of their research cast light on the fact that the target of the miR-372 gene is TXNIP which is inversely correlated with miR-372. While TXNIP is upgraded through MAPK/ERK inhibitors (name as U0126, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="FR180204">FR180204</ext-link>, and WAY265506), miR-372 expression remarkably reduces in CRC cell lines [<xref rid="bib92" ref-type="bibr">92</xref>]. The other study conducted by Wang et al. (2018) is concerned with other dimensions of miR-372 features. Their research indicated that decreasing some pathways and signals enhances the stemness of CRCs. The overexpression of miR-372 causes phenotype cancer stem cells (CSC) to enhance in the body. Besides, the researchers realized that the high level of miR-372 leads to resistance to the chemotherapeutic drug in patients with CRC. In a sense, even miR-372 inhibitor (TuD) could not remove the remarkable effect of drug resistance. CRC cell invasion, migration, tumor formation, and the protein levels of CSC markers (CD44 and CD26) were boosted by overexpression of miR-372. A set of signaling pathways called Hedgehog, c-Myc, and Nanog enhance by enforced expression of miR-372. However, some signaling pathways (NF&#312;B, SP1, MAPK/Erk, and vitamin D) and a series of genes such as RELA, VDR, SETD7, SPOP, TRERF1, ZNF367, and MTUS1 lower with the existence of overexpression of miR-372. The investigator elicited three genes (VDR, SPOP, and SETD7) amid mentioned genes to meticulously be considered. Furthermore, they asserted that decreasing these genes contributes to upgrading the CSD population. In fact, such genes play a fundamental role in suppressing tumor formation in the body. Also, the researchers worked on another signaling pathway named Wnt/&#946;-catenin, which is significant in maintaining CRC stem cells and a sharp decline in the NF&#312;B pathway. In effect, cross-talking between Wnt/&#946;-catenin and NF&#312;B in CRC cells is created by miR-372 expression, as key effectors of Wnt/&#946;-catenin signaling [<xref rid="bib93" ref-type="bibr">93</xref>].</p><p id="p0135">Gallbladder cancer (GBC) is the most common and lowest survival cancer among all biliary tract cancers [<xref rid="bib94" ref-type="bibr">94</xref>,<xref rid="bib95" ref-type="bibr">95</xref>]. An estimated 11980 new cases and 4310 deaths of biliary tract cancers will be diagnosed in 2021 [<xref rid="bib2" ref-type="bibr">2</xref>]. There is merely one study focusing on the association between miR-372 and GBC. Zhou et al. researched the relationship of hsa-miR-372 with GBC, and they indicated that in GBC, the level of hsa-miR-372 expression, whose target is likely CLIC1 (Chloride intracellular channel 1), is lower. Even though the decline in miR-372 expression is associated with an advanced and aggressive tumor, shorter overall survival, and metastasis, the decrease of hsa-miR-372 expression is not correlated with age, sex, tumor size, and gallbladder stones [<xref rid="bib96" ref-type="bibr">96</xref>].</p><p id="p0140">Toll death of pancreatic cancer is the highest among other gastrointestinal cancers since most patients are diagnosed at the advanced stage and metastasis [<xref rid="bib97" ref-type="bibr">97</xref>,<xref rid="bib98" ref-type="bibr">98</xref>]. The 5-year survival rate is approximately 10% worldwide [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib76" ref-type="bibr">76</xref>,<xref rid="bib97" ref-type="bibr">97</xref>]. As reported in 2020, the number of new cases and deaths are 49,5773 and 46,6003, respectively [<xref rid="bib4" ref-type="bibr">4</xref>]. In doing so, early detection and treatment of this insidious cancer are important in saving patients and increasing their overall survival. s, many experimental studies are working on the biomarker of pancreas cancer, a microRNA, to find a way to diagnose and treat in the earlier stage of the disease. Just one research indicates the association between miR-372 and pancreas cancer described in the process of autophagy [<xref rid="bib99" ref-type="bibr">99</xref>]. Chen et al. demonstrated miR-372 expression decline in human pancreatic adenocarcinoma cells (HPAC). The function of miR-372 is to inhibit proliferation, invasion, migration, and autophagy of HPAC and increase cell apoptosis. A UNC5Q-like kinase (ULK1), a target of miR-372, is inversely related to miR-372. The augmentation of miR-372 expression reduces both mRNA and protein levels of ULK1 and phosphorylation. ULK1 causes the autophagy process to begin. The inhibitor of ULK1 is mTOR. However, this process is regulated by the adenosine monophosphate-activated protein kinase (AMPK). Autophagy is in relationship with LC3, whose subgroup is named LC3-II, which boosts HPAC. The autophagy substrate is P62, increasing in HPAC. Both LC3-II and P62 levels are inverse associated with miR-372. Si-ULK1, which is an inhibitor of the autophagy process, inhibits ULK1 and LC3II but causes an increase of P62 and LC3-I. All the impacts of miR-372 on HPAC are reversed through the inhibition of ULK1 with chloroquine treatment. The decline in LC3-II is through the knockdown of ULK1, but LC3-II increases by exogenous ULK1 and chloroquine. The level of p62 increases by the knockdown of ULK1. Nevertheless, the extent of P62 is lowered by exogenous ULK1. These processes highlight that miR-372 affects HPAC survival via targeting p62 and adjusting autophagy by targeting ULK1 [<xref rid="bib99" ref-type="bibr">99</xref>]. A plethora of research has yet to be conducted in this field. However, another study investigated by Yu et al. shed light on the fact that the level of miR-372 expression decreases in pancreatic intraepithelial neoplasia (PanIN) [<xref rid="bib100" ref-type="bibr">100</xref>].</p></sec><sec id="sec1.7"><label>1.7</label><title>MiR-372 and breast cancer</title><p id="p0145">Breast cancer (BC) is considered the most ubiquitous cancer diagnosed among women worldwide, except for skin cancer. Approximately 41,760 out of 268,600 women diagnosed with invasive breast cancer will be dead. In the same vein, worldwide, a large population of women, constituting roughly 13%, will be diagnosed with invasive breast cancer [<xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>, <xref rid="bib103" ref-type="bibr">[103]</xref>]. Many studies shed light on the fact that the mortality rate of BC, which is common among women, is exceedingly high after lung cancer in the US [<xref rid="bib101" ref-type="bibr">101</xref>,<xref rid="bib104" ref-type="bibr">104</xref>]. However, the rate of the BC toll remarkably mitigates in developed countries like the US because of innovative therapeutic and diagnostic methods [<xref rid="bib105" ref-type="bibr">105</xref>]. Fundamentally, breast cancer is categorized in terms of molecular and histological subtypes. The former is contingent on two hormone receptors (estrogen and progesterone) and the expression of the human epidermal growth factor receptor 2 (HER2-positive/HER2-negative) protein. The latter is divided into invasive ductal carcinoma, invasive lobular carcinoma, and mixed ductal/lobular carcinomas. The most common breast cancer subtype is HR-positive/HER2-negative and invasive ductal carcinoma [<xref rid="bib101" ref-type="bibr">101</xref>,<xref rid="bib106" ref-type="bibr">106</xref>]. Over the past few years, one of the biomarkers that have stood out in breast cancer progression is essentially microRNA playing an essential role in carcinogenesis [<xref rid="bib107" ref-type="bibr">107</xref>]. In this study, we review assorted research regarding the role of miR-372 in BC cases.</p><p id="p0150">The outcome of one research conducted by Zhao et al. asserted that the expression of miR-372, whose target is E2F1, is downregulated in both BC specimens and cell lines since the responsibility of miR-372 is tumor suppressive in BC development. In a sense, this research demonstrated that E2F1 is upregulated in human breast cancer tissues compared to their close normal tissues, and also, there is a significantly negative correlation between the mRNA level of E2F1 and miR-372 levels in BC tissues. Moreover, their research asserted that miR-372 prohibits proliferation and results in apoptosis in breast cancer through targeting E2F1 [<xref rid="bib31" ref-type="bibr">31</xref>]. In contrast with such research, another research investigated by Cheng et al. and Fan et al. provided a different perspective on miR-372. They contended that miR-372 is considerably upgraded in the BC tissues and cell lines. In doing so, the downregulation of miR-372 impedes the increase of BC cells in the body. They shed light on that miR-372 plays an oncogenic role in the BC cells [<xref rid="bib108" ref-type="bibr">108</xref>,<xref rid="bib109" ref-type="bibr">109</xref>].</p><p id="p0155">What&#8217;s more, Cheng et al. maintained that large tumor suppressor kinase 2 (LATS2) is the target gene of miR-372 in the BC tissues. LATS2 downregulation reverses the anti-proliferation effect of AS-miR-327 in breast cancer cells [<xref rid="bib108" ref-type="bibr">108</xref>]. Along similar lines, Fan et al. presented that the increase of miR-372-3p expression culminated in leading to shorter survival time in breast carcinoma patients, and also, although it is tied up with two leading factors called tumor size and tumor stage, it is by no means related to age, gender, and lymph node metastasis. In doing so, miR-372-3p is considered a prognostic factor for BC cases. Besides, they stated that miR-372-3p stimulates breast carcinoma cells&#8217; epithelial-mesenchymal transition (EMT) via activating the pathway of Wnt. MiR-372-3p got attached to DKK1, which is the inhibitor of the Wnt pathway. In reality, there is a reverse relationship between mir-372 and DKK1 [<xref rid="bib109" ref-type="bibr">109</xref>]. Nevertheless, taken together, it is still required that other prospective researchers work on the impact of miR-372 on breast cancer cases.</p></sec><sec id="sec1.8"><label>1.8</label><title>miR-372 and osteosarcoma</title><p id="p0160">Osteosarcoma (OS) is the most prevalent malignant bone tumor that frequently occurs in children and young adults dedicated %3.4 of all childhood cancers to itself [<xref rid="bib110" ref-type="bibr">110</xref>]. OS mainly occurs in the long bones&#8217; metaphysis, especially the distal femur or proximal tibia around the knee [<xref rid="bib111" ref-type="bibr">111</xref>]. Some risk factors related to OS occurrence: Age, gender, socio-economic status, height, environmental features, and genetics [<xref rid="bib112" ref-type="bibr">112</xref>]. Genetic research is fundamental in OS prevention and treatment strategies, in light of the most cardinal cause of OS is genetic mutations [<xref rid="bib113" ref-type="bibr">113</xref>]. Countless mutations could potentially predispose to OS [<xref rid="bib114" ref-type="bibr">114</xref>]. It is found that miRNA dysregulation may promote or inhibit OS metastasis [<xref rid="bib115" ref-type="bibr">115</xref>]. It has been realized that RNA dysregulation, including miRNA dysregulation, has a decisive role in OS initiation and progression [<xref rid="bib116" ref-type="bibr">116</xref>]. Xu et al. revealed that miR-372 is presented as a tumor suppressor gene in OS. They proved that miR-372 over-expression inhibits the proliferation, migration, and invasion of OS cells in vivo and <italic toggle="yes">in vitro</italic>. MiR-372 did its tumor suppressor part by suppressing FXYD6 mRNA [<xref rid="bib117" ref-type="bibr">117</xref>]. Two years later, Gao et al. unveiled that Circ_0001721, a circular RNA, was upregulated in OS more than in normal tissues. Circ_0001721 knockdown inhibited glycolysis, cell proliferation, cell migration, invasion, and epithelial-to-mesenchymal transition (EMT) and promoted apoptosis by regulating miR-372 through the MAPK7 pathway. MiR-372 appeared as a tumor suppressor through the MAPK7 axis [<xref rid="bib118" ref-type="bibr">118</xref>]. In another study, Li et al. proved that HULC has a common suppressive effect on miR-372 expression. Also, the knockdown of miR-372 leads to the proliferation, migration, and invasion of OS cells <italic toggle="yes">in vitro</italic>. HULC could cause OS tumor growth and metastasis through the miR-372/HMGB1 axis. Thus, miR-372 has a suppressive role in OS by inhibiting proliferation, migration, and invasion by targeting HMGB1 [<xref rid="bib119" ref-type="bibr">119</xref>].</p></sec><sec id="sec1.9"><label>1.9</label><title>miR-372 and genitourinary cancers</title><p id="p0165">Genitourinary (GU) system cancers are one of the most prevalent malignancies in clinical practice, accounting for an estimated 540,970 new cancer patients and 101,050 deaths in 2021 in the United States [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib120" ref-type="bibr">120</xref>]. Furthermore, GU malignancies are higher in men than in women, especially in bladder cancer subjects; it is as much as three times higher. GU neoplasms are still responsible for millions of fatalities annually, despite current diagnosis breakthrough procedures, notably imaging techniques and therapy opportunities [<xref rid="bib120" ref-type="bibr">120</xref>]. In GU cancers, many investigations demonstrate that miR-372 possesses tumor-suppressive characteristics.</p><p id="p0170">Bladder cancer is the second most prevalent urinary tract malignancy, assigned the highest lifetime treatment costs per patient in all cancers [<xref rid="bib121" ref-type="bibr">121</xref>]. Bladder cancer is responsible for %3 of cancer diagnoses worldwide and is the sixth most incident neoplasm in the US. It mainly occurs in old ages, whereas %90 of new diagnoses are 55 years of age and older [<xref rid="bib122" ref-type="bibr">122</xref>]. Some risk factors, including smoking, environmental and occupational exposures, chronic bladder irritation/infections, and congenital abnormalities, are responsible for bladder cancer [<xref rid="bib123" ref-type="bibr">123</xref>]. Gene abnormalities ranging from single DNA mutations to complete or partial chromosomal deletions can come to cell cycle disorders. Several studies proposed that PI3K signaling pathway may relate to bladder cancer development and progression [<xref rid="bib124" ref-type="bibr">124</xref>]. In 2020 Liu et al. concluded that CLUB4 levels over-expression is concerning bladder cancer and could cause increased motility, invasiveness, stemness, and chemoresistance in bladder cancer cells. CLUB4 plays its role by upregulating PIK3CA by repressing miR-372. It is better to mention that miR-372 as a tumor suppressor could decrease PIK3CA expression and inhibit the migration and invasion of bladder cancer cells. So, they established that CLUB4B-miR-372/373-PIK3CA/AKT axis has a crucial role in bladder cancer pathogenesis with important prognostic and therapeutic implications [<xref rid="bib125" ref-type="bibr">125</xref>].</p><p id="p0175">Cervical cancer has taken third place among the most common cancers in women worldwide, mainly occurring in low and middle-income countries with the peak age of 35&#8211;45 [<xref rid="bib126" ref-type="bibr">126</xref>,<xref rid="bib127" ref-type="bibr">127</xref>]. Most cervical cancer cases are infected by the human papillomavirus (HPV) [<xref rid="bib126" ref-type="bibr">126</xref>]. Most infections are cleared by the immune system, but a few subtypes, including HPV16 and HPV18, continue to exist and express E6 and E7. These viral oncogenes (E6 and E7) could cause increased genomic instability, somatic mutation accumulation, and HPV integration into the host genome, leading to cervical cancer [<xref rid="bib128" ref-type="bibr">128</xref>]. Typically, it takes 5&#8211;10 years between precancer diagnoses and the initial oncogenic infection. %30 of high-grade precancers will turn into invasive cancers finally [<xref rid="bib127" ref-type="bibr">127</xref>]. In 2011, Tian et al. indicated that miR-372 has a tumor suppressor function in cervical cancer. They found that miR-372 was down-regulated in cancer cells compared to adjacent normal tissues, whereas cyclinA1 and CDK2 were up-regulated as the targets of miR-372. When miR-372 was over-expressed, expression of the EGFP receptor, which contains 3&#8242;-UTR of cyclinA1 and CDK2, was inhibited. In addition, they demonstrated that CDK2 and cyclinA1 over-expression quickened DNA replication in S-phase, entry into G2, and vice versa. So miR-372 does its anti-oncogenic role by down-regulating the cell cycle genes, CDK2, and cyclinA1, controlling cell cycle growth and its progression [<xref rid="bib129" ref-type="bibr">129</xref>].</p><p id="p0180">Endometrial cancer &#8211; the most gynecologic cancer in developed countries &#8211; is women's 4th most prevalent cancer. Unbalanced increase of estrogen via early menarche, late menopause, exposure to tamoxifen, nulliparity, and obesity as significant risk factors have a crucial role in developing endometrial cancer [<xref rid="bib130" ref-type="bibr">130</xref>,<xref rid="bib131" ref-type="bibr">131</xref>]. Typically post-menopausal obese women are the most common cases of endometrial cancer, but its incidence is dramatically rising among young women due to earlier-onset obesity [<xref rid="bib132" ref-type="bibr">132</xref>]. Carcinoma is the most common form of endometrial cancer [<xref rid="bib133" ref-type="bibr">133</xref>]. In 2015, Liu et al. found that miR-372 has a tumor suppressor role in endometrial carcinoma. In that study, miR-372 expression was lower in cancer cells than in normal cells, and miR-372 over-expression suppressed the proliferation of endometrial carcinoma cells. RhoC, Cyclin A1, and CDK2 as miR-372 targets with oncogene characteristics were down-regulated when miR-372 over-expressed. So miR-372/RhoC. miR-372/Cyclin A1 and miR-372/CDK2 pathways may collectively be a part of miR-372 anti-oncogenic properties in endometrial carcinoma [<xref rid="bib134" ref-type="bibr">134</xref>].</p><p id="p0185">Ovarian cancer (OC) is the third-ranked of the most common gynecologic cancers, has the worst prognosis and the highest mortality rates, three times more lethal than breast cancer [<xref rid="bib135" ref-type="bibr">135</xref>]. OC is comprehended by heterogeneous malignancies with various etiology and molecular biology; its prevalence may differ between races and countries because of several factors, including genetics and economy (126). The most common form of ovarian cancer is serous carcinoma [<xref rid="bib136" ref-type="bibr">136</xref>]. In 2017, Guan et al. stated that miR-372 over-expression has a prominent role in tumor growth inhibiting as a tumor suppressor in ovarian carcinoma. In that study, they concluded that miR-372 over-expression could result in three major outcomes: 1) suppress ovarian cancer cells proliferation and induce cell cycle arrest, 2) ATAD2, LATS2, P62, DKK1, and Cyclin A1 down-regulation as responsible for cell proliferation and 3) cell apoptosis promotion. Thus miR-372 could be a critical target in future ovarian carcinoma treatments [<xref rid="bib137" ref-type="bibr">137</xref>].</p><p id="p0190">Renal cell carcinoma (RCC) is the most common malignancy originating from the kidney. Typically, RCC is asymptomatic, leading to late diagnosis, making RCC the most lethal genitourinary cancer [<xref rid="bib138" ref-type="bibr">138</xref>]. The 5-year survival is below %10, and more than %20 of patients who went through nephrectomy will experience metastasis during follow-up, making RCC a poor prognosis [<xref rid="bib139" ref-type="bibr">139</xref>]. The most common type of RCC is the clear cell type accounting for %80 of all RCC cases [<xref rid="bib140" ref-type="bibr">140</xref>]. MiRNAs, as the most well-known non-coding RNAs, are extensively investigated for their critical role in cancer to make it a potential target for advancing the diagnosis, prognosis, and therapeutic implications [<xref rid="bib141" ref-type="bibr">141</xref>]. In 2015, Huang et al. concluded that miR-372 has an anti-oncogenic role in RCC. miR-372 over-expression could inhibit cell proliferation and invasion <italic toggle="yes">in vitro</italic>. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of miR-372, was responsible for cell proliferation and invasion. miR-372 over-expression could lead to IGF2BP1 down-regulation to do its anti-oncogenic part in RCC [<xref rid="bib142" ref-type="bibr">142</xref>]. In another study in 2018, Ji et al. revealed another pathway of miR-372. They presented that miR-372 expression was down-regulated in RCC tissues, and it is significantly associated with the poor survival rate and adverse clinical characteristics in RCC patients. miR-372 suppressed EMT and metastasis by ATAD2 targeting, suggesting that miR-372/ATAD2 axis have an anti-oncogenic role in RCC and may be a potential therapeutic biomarker for RCC treatment [<xref rid="bib143" ref-type="bibr">143</xref>].</p><p id="p0195">Prostate cancer (PC) ranks first among the most cancers diagnosed in men worldwide [<xref rid="bib144" ref-type="bibr">144</xref>]. Age and family history are the most critical risk factors for PC [<xref rid="bib145" ref-type="bibr">145</xref>]. Prostate malignant neoplasms mostly originated and differentiated from epithelial tissue and are carcinomas [<xref rid="bib146" ref-type="bibr">146</xref>]. Multifocal nature of the disease has made the diagnosis challenging [<xref rid="bib147" ref-type="bibr">147</xref>]. Multiple studies have defined a genetic route in prostate cancer, including several genetic and epigenetic pathways [<xref rid="bib148" ref-type="bibr">148</xref>]. In 2016, Kong et al. indicated that miR-372 has tumor suppressor function by regulating P65. They resulted that miR-372 could decrease migration and invasion in prostate cancer cells by negative regulation of P65. Thus miR-372 as an anti-oncogenic could be set for the prevention, diagnosis, and treatment of prostate cancer patients [<xref rid="bib149" ref-type="bibr">149</xref>].</p><p id="p0200">Conversely in another study, Cao et al. conclude that over-expression of miR-372 boosts tumor cell proliferation and migration via targeting LATS2. They indicated that LATS2 works as a tumor suppressor gene. They indicated that repressing the over-expression of miR-372 by arsenic sulfide (As4S4) could prevent cancer cell proliferation and migration [<xref rid="bib150" ref-type="bibr">150</xref>].</p><p id="p0205">Testicular germ cell tumors (TGCTs) are the most common malignancy in young men, extensively classified into seminomatous and non-seminomatous groups [<xref rid="bib151" ref-type="bibr">151</xref>]. Generally, to speak freestanding, Testicular tumors follow %90 rules; more than %90 are malignant, more than %90 are of germ cells origin (TGCTs), and more than %90 are sporadic and diagnosed in 20&#8211;45 years of age [<xref rid="bib152" ref-type="bibr">152</xref>]. TGCTs have an outstanding overall cure rate and prognosis [<xref rid="bib153" ref-type="bibr">153</xref>]. Cryptorchidism, prior GCT, subfertility, sexual differentiation disorder, and positive family history are related risk factors for TGCT. TGCT is likely driven by polygenic variation. Serum miRNA is starting to appear as a diagnostic and therapeutic biomarker in TGCT patients [<xref rid="bib151" ref-type="bibr">151</xref>]. Despite most of the studies about genitourinary tumors mentioned above, miR-372 has an oncogenic role in testicular germ cell tumors. In 2006, Voorhoeve et al. identified miR-372 in an oncogenic way, letting the primary human cells' proliferation and tumorigenesis. miR-372 could conceal RAS and active wild-type P53 by neutralizing P53-mediated CDK inhibition via targeting the expression of the tumor suppressor LATS2. So, numbing the P53 pathway allows tumorigenicity which could introduce miR-372 as an oncogene in TGCT [<xref rid="bib154" ref-type="bibr">154</xref>]. Syring et al. stated that miRNA detection was precise for testicular cancer. The mean serum miR-372 was significantly increased in TGCT patients. miR-372 levels had a %74 diagnostic sensitivity with a %100 specificity, while tumor markers including Alpha Fito Protein, Human Chorionic Gonadotropin and Lactate Dehydrogenase had a combined sensitivity of %60 for testicular cancers [<xref rid="bib155" ref-type="bibr">155</xref>,<xref rid="bib156" ref-type="bibr">156</xref>].</p></sec></sec><sec id="sec2"><label>2</label><title>Conclusions and perspectives</title><p id="p0210">The frequency of many cancers in humans has increased over the past few decades, despite the fact that there has been a general improvement in lifestyle, consciousness, and the living environment of humans. However, despite the fact that many researchers are always striving to understand the detailed processes of carcinogenesis and that each year new generations of anticancer medications are launched, the survival rate of cancer patients has remained steady, and only a little amount of improvement has been accomplished.</p><p id="p0215">Studies conducted in recent years have revealed that restoring normal levels of improperly produced miRNA can influence the growth of malignant tumors, and as a result, can function as an effective molecular targeted medicine for the treatment of cancers [<xref rid="bib157" ref-type="bibr">157</xref>,<xref rid="bib158" ref-type="bibr">158</xref>].</p><p id="p0220">Naked miRNAs have a short half-life in the blood due to the breakdown of nucleases that occur naturally in the body. This is despite the fact that it has been demonstrated that miRNAs are promising and effective therapeutic medicines <italic toggle="yes">in vitro</italic>. Therefore, the limited bio-availability of nucleic acid therapeutics in vivo presents a significant obstacle for the development of miRNAs as potential anti-cancer medications. It is impossible to ignore the fact that numerous systems or carriers for miRNA have been widely advocated. These systems or carriers include nanoparticles, modifications to ncRNA, and oncolytic adenovirus methods [<xref rid="bib159" ref-type="bibr">159</xref>]. Carriers for microRNA that are based on nanoparticles are the most common approach [<xref rid="bib160" ref-type="bibr">160</xref>]. For instance, miR-21 has been found to play a role in the progression of multiple cancers as a tumor promoter [<xref rid="bib161" ref-type="bibr">161</xref>]. Several researchers attempted to transport miR-21 antisense oligonucleotides in order to exhibit an anti-cancer function. Satisfying effects were reached in cases of pancreatic cancer, breast cancer, glioblastoma, and other cancers [<xref rid="bib158" ref-type="bibr">158</xref>,<xref rid="bib162" ref-type="bibr">162</xref>,<xref rid="bib163" ref-type="bibr">163</xref>]. In light of the intriguing function that miR-372 plays in suppressing the growth of tumors, we think that in the future, therapeutic nucleic acid medications based on miR-372 could be very effective.</p><p id="p0225">It has been hypothesized that the miR-372 has significant tumor-suppressing effects in a variety of human malignancies. Notably, a number of studies suggested that the ceRNA mechanism would play an essential role in miR-372-mediated tumor suppression. Based on our analysis of the lncRNA/CircRNA-miR-372 networks, we come to the conclusion presented in <xref rid="tbl2" ref-type="table">Table 2</xref>. The ceRNA mechanism primarily incorporates three different types of RNAs, including mRNA, pseudogene transcripts, and lncRNA; however, circRNA has recently followed in the footsteps of lncRNA to become a novel hotspot in the field of ceRNA family. The next step in elucidating the role of miR-372 in human cancers will involve determining whether or not circRNAs are collaborators who take part in the miR-372-mediated regulation of tumor growth.</p><p id="p0230">In conclusion, the research to far show that miR-372 is both up- and down-regulated in various malignancies. Additionally, it has a dual function in various types of cancer, acting both as an oncogene and a tumor suppressor in different organs under different circumstances. Future studies should delve deeper into this enormous controversy. Particularly, the focus of current research is mostly on clinical tissue samples and cell culture. However, more studies with a clinical focus and animal models are needed to clarify miR-372's precise function in various malignancies. Also, the involvement of miR-372 has not yet been explored in some of the tumors, particularly those coming from the hematopoietic and lymphoid tissues, thus it is strongly advised to investigate the functional role of miR-372 in tumor of hematopoietic and lymphoid tissues.</p><p id="p0235">It is a widely held belief that the treatment of human tumors typically involves a synergistic approach that includes elements of surgery, radiotherapy, and chemotherapy [<xref rid="bib164" ref-type="bibr">164</xref>]. Because of this, doing in-depth research into the roles that miR-372 plays in chemo-sensitization and radio-sensitization are of the utmost relevance.</p><sec id="sec2.1"><label>2.1</label><title>Limitations of the study</title><p id="p0240">The most important limitation of research related to miR-372 is the lack of clinical trial studies, so it seems that designing and conducting clinical trial studies is necessary to confirm the <italic toggle="yes">in vitro</italic> and in vivo research done. Also, the authors should consider genomic-directed stratifications during the design and enrollment of clinical trials.</p></sec></sec><sec id="sec3"><title>Author contribution statement</title><p id="p0245">All authors listed have significantly contributed to the development and the writing of this article.</p></sec><sec sec-type="data-availability" id="sec4"><title>Data availability statement</title><p id="p0250">Data included in article/supp. material/referenced in article.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0260">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Calin</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>MicroRNA signatures in human cancers</article-title><source>Nat. Rev. Cancer</source><volume>6</volume><issue>11</issue><year>2006</year><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">17060945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1997</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Cancer statistics, 2021</article-title><source>CA A Cancer J. Clin.</source><volume>71</volume><issue>1</issue><year>2021</year><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The ever-increasing importance of cancer as a leading cause of premature death worldwide</article-title><source>Cancer</source><volume>127</volume><issue>16</issue><year>2021</year><fpage>3029</fpage><lpage>3030</lpage><pub-id pub-id-type="pmid">34086348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33587</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA A Cancer J. Clin.</source><volume>71</volume><issue>3</issue><year>2021</year><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Sahebi-Fakhrabad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Handfield</surname><given-names>R.</given-names></name></person-group><article-title>Evaluating state-level prescription drug monitoring program (PDMP) and pill mill effects on opioid consumption in pharmaceutical supply chain</article-title><source>Healthcare</source><volume>11</volume><year>2023</year><pub-id pub-id-type="doi">10.3390/healthcare11030437</pub-id><pub-id pub-id-type="pmcid">PMC9914561</pub-id><pub-id pub-id-type="pmid">36767012</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Mahabady</surname><given-names>M.K.</given-names></name><etal/></person-group><article-title>Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: mechanisms of initiation, progression, and drug sensitivity</article-title><source>J. Cell. Physiol.</source><volume>237</volume><issue>5</issue><year>2022</year><fpage>2309</fpage><lpage>2344</lpage><pub-id pub-id-type="pmid">35437787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.30751</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Bartel</surname><given-names>D.P.</given-names></name></person-group><article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title><source>Cell</source><volume>116</volume><issue>2</issue><year>2004</year><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">14744438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(04)00045-5</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Ambros</surname><given-names>V.</given-names></name></person-group><article-title>microRNAs: tiny regulators with great potential</article-title><source>Cell</source><volume>107</volume><issue>7</issue><year>2001</year><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">11779458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(01)00616-x</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Vasudevan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Steitz</surname><given-names>J.A.</given-names></name></person-group><article-title>Switching from repression to activation: microRNAs can up-regulate translation</article-title><source>Science</source><volume>318</volume><issue>5858</issue><year>2007</year><fpage>1931</fpage><lpage>1934</lpage><pub-id pub-id-type="pmid">18048652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1149460</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Fabian</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Sonenberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Filipowicz</surname><given-names>W.</given-names></name></person-group><article-title>Regulation of mRNA translation and stability by microRNAs</article-title><source>Annu. Rev. Biochem.</source><volume>79</volume><year>2010</year><fpage>351</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">20533884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-060308-103103</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Feinbaum</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Ambros</surname><given-names>V.</given-names></name></person-group><article-title>The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14</article-title><source>Cell</source><volume>75</volume><issue>5</issue><year>1993</year><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">8252621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(93)90529-y</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Wightman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ruvkun</surname><given-names>G.</given-names></name></person-group><article-title>Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans</article-title><source>Cell</source><volume>75</volume><issue>5</issue><year>1993</year><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">8252622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(93)90530-4</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name></person-group><article-title>MicroRNA: an emerging therapeutic target and intervention tool</article-title><source>Int. J. Mol. Sci.</source><volume>9</volume><issue>6</issue><year>2008</year><fpage>978</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">19325841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms9060978</pub-id><pub-id pub-id-type="pmcid">PMC2658779</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>A.</given-names></name></person-group><article-title>MicroRNAs in cancer</article-title><source>Annu. Rev. Pathol.</source><volume>4</volume><year>2009</year><fpage>199</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">18817506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pathol.4.110807.092222</pub-id><pub-id pub-id-type="pmcid">PMC2769253</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Alizadeh-Fanalou</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MiR-613 promotes cell death in breast cancer cells by downregulation of nicotinamide phosphoribosyltransferase and reduction of NAD</article-title><source>DNA Cell Biol.</source><volume>40</volume><issue>7</issue><year>2021</year><fpage>1026</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">34101492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dna.2021.0330</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Behl</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Intercalating the role of MicroRNAs in cancer: as enemy or protector</article-title><source>Asian Pac. J. Cancer Prev. APJCP: Asian Pac. J. Cancer Prev. APJCP</source><volume>21</volume><issue>3</issue><year>2020</year><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">32212783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31557/APJCP.2020.21.3.593</pub-id><pub-id pub-id-type="pmcid">PMC7437313</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Alizadeh-Fanalou</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dysregulation of microRNAs regulating survivin in CD4+ T cells in multiple sclerosis</article-title><source>Mult. Scler. Relat. Disord.</source><volume>44</volume><year>2020</year><object-id pub-id-type="publisher-id">102303</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2020.102303</pub-id><pub-id pub-id-type="pmid">32599467</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Ghaffari</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Captopril and spironolactone can attenuate diabetic nephropathy in wistar rats by targeting ABCA1 and microRNA-33</article-title><source>Curr. Pharmaceut. Des.</source><volume>28</volume><issue>16</issue><year>2022</year><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612828666220401143249</pub-id><pub-id pub-id-type="pmid">35366766</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Tavakoli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Transcriptional regulation of T-bet, GATA3, ROR&lt;gamma&gt;T, HERV-K env, Syncytin-1, microRNA-9, 192 and 205 induced by nisin in colorectal cancer cell lines (SW480, HCT116) and human peripheral blood mononuclear cell</article-title><source>Gene Reports</source><volume>23</volume><year>2021</year><object-id pub-id-type="publisher-id">101025</object-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Jorge</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>MicroRNAs: understanding their role in gene expression and cancer</article-title><source>Einstein (Sao Paulo)</source><volume>19</volume><year>2021</year><fpage>eRB5996</fpage><pub-id pub-id-type="pmid">34287566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31744/einstein_journal/2021RB5996</pub-id><pub-id pub-id-type="pmcid">PMC8277234</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>microRNAs as oncogenes and tumor suppressors</article-title><source>Dev. Biol.</source><volume>302</volume><issue>1</issue><year>2007</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16989803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ydbio.2006.08.028</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Dalmay</surname><given-names>T.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.R.</given-names></name></person-group><article-title>MicroRNAs and the hallmarks of cancer</article-title><source>Oncogene</source><volume>25</volume><issue>46</issue><year>2006</year><fpage>6170</fpage><lpage>6175</lpage><pub-id pub-id-type="pmid">17028596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1209911</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Gheytanchi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis</article-title><source>Cancer Cell Int.</source><volume>23</volume><issue>1</issue><year>2023</year><fpage>10</fpage><pub-id pub-id-type="pmid">36670440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-02851-8</pub-id><pub-id pub-id-type="pmcid">PMC9862982</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Alizadeh-Fanalou</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dual role of microRNA-1297 in the suppression and progression of human malignancies</article-title><source>Biomed. Pharmacother.</source><volume>141</volume><year>2021</year><object-id pub-id-type="publisher-id">111863</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111863</pub-id><pub-id pub-id-type="pmid">34243098</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Pfister</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes</article-title><source>Acta Neuropathol.</source><volume>117</volume><issue>4</issue><year>2009</year><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">19057917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-008-0467-y</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Voorhoeve</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors</article-title><source>Cell</source><volume>124</volume><issue>6</issue><year>2006</year><fpage>1169</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">16564011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2006.02.037</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Yasukawa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The microRNAs miR-302b and miR-372 regulate mitochondrial metabolism via the SLC25A12 transporter, which controls MAVS-mediated antiviral innate immunity</article-title><source>J. Biol. Chem.</source><volume>295</volume><issue>2</issue><year>2020</year><fpage>444</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">31767682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA119.010511</pub-id><pub-id pub-id-type="pmcid">PMC6956542</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Increased levels of miR-372 correlate with disease progression in patients with hyperlipidemic acute pancreatitis</article-title><source>Exp. Ther. Med.</source><volume>19</volume><issue>6</issue><year>2020</year><fpage>3845</fpage><lpage>3850</lpage><pub-id pub-id-type="pmid">32346449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2020.8609</pub-id><pub-id pub-id-type="pmcid">PMC7185087</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>N.D.</given-names></name><etal/></person-group><article-title>A miR-372/let-7 Axis regulates human germ versus somatic cell fates</article-title><source>Stem Cell.</source><volume>34</volume><issue>7</issue><year>2016</year><fpage>1985</fpage><lpage>1991</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/stem.2378</pub-id><pub-id pub-id-type="pmcid">PMC5145290</pub-id><pub-id pub-id-type="pmid">27066911</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Subramanyam</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells</article-title><source>Nat. Biotechnol.</source><volume>29</volume><issue>5</issue><year>2011</year><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">21490602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1862</pub-id><pub-id pub-id-type="pmcid">PMC3685579</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.X.</given-names></name><etal/></person-group><article-title>microRNA-372 inhibits proliferation and induces apoptosis in human breast cancer cells by directly targeting E2F1</article-title><source>Mol. Med. Rep.</source><volume>16</volume><issue>6</issue><year>2017</year><fpage>8069</fpage><lpage>8075</lpage><pub-id pub-id-type="pmid">28944922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2017.7591</pub-id><pub-id pub-id-type="pmcid">PMC5779890</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MicroRNA-372 is associated with poor prognosis in colorectal cancer</article-title><source>Oncology</source><volume>82</volume><issue>4</issue><year>2012</year><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">22456107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000336809</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma</article-title><source>Mol. Cell. Biochem.</source><volume>375</volume><issue>1&#8211;2</issue><year>2013</year><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">23291979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-012-1521-6</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2</article-title><source>J. Cell. Biochem.</source><volume>116</volume><issue>2</issue><year>2015</year><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">25160587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.24949</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><etal/></person-group><article-title>FER1L4/miR-372/E2F1 works as a ceRNA system to regulate the proliferation and cell cycle of glioma cells</article-title><source>J. Cell Mol. Med.</source><volume>23</volume><issue>5</issue><year>2019</year><fpage>3224</fpage><lpage>3233</lpage><pub-id pub-id-type="pmid">30887657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.14198</pub-id><pub-id pub-id-type="pmcid">PMC6484322</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Moradi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Lower expression of miR-10a in coronary artery disease and its association with pro/anti-inflammatory cytokines</article-title><source>Clin. Lab.</source><volume>64</volume><issue>5</issue><year>2018</year><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">29739060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7754/Clin.Lab.2018.171222</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo</article-title><source>Oncotarget</source><volume>6</volume><issue>8</issue><year>2015</year><fpage>6062</fpage><lpage>6075</lpage><pub-id pub-id-type="pmid">25714028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.3340</pub-id><pub-id pub-id-type="pmcid">PMC4467422</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Debakey</surname><given-names>M.</given-names></name></person-group><article-title>Carcinoma of the lung and tobacco smoking: a historical perspective</article-title><source>Ochsner J.</source><volume>1</volume><issue>3</issue><year>1999</year><fpage>106</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">21845127</pub-id><pub-id pub-id-type="pmcid">PMC3145445</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Global incidence of oesophageal cancer by histological subtype in 2012</article-title><source>Gut</source><volume>64</volume><issue>3</issue><year>2015</year><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">25320104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2014-308124</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Risk factors for lung cancer worldwide</article-title><source>Eur. Respir. J.</source><volume>48</volume><issue>3</issue><year>2016</year><fpage>889</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">27174888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00359-2016</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA A Cancer J. Clin.</source><volume>66</volume><issue>1</issue><year>2016</year><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21332</pub-id><pub-id pub-id-type="pmid">26742998</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Dela Cruz</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Tanoue</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Matthay</surname><given-names>R.A.</given-names></name></person-group><article-title>Lung cancer: epidemiology, etiology, and prevention</article-title><source>Clin. Chest Med.</source><volume>32</volume><issue>4</issue><year>2011</year><fpage>605</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">22054876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccm.2011.09.001</pub-id><pub-id pub-id-type="pmcid">PMC3864624</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>de Groot</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>The epidemiology of lung cancer</article-title><source>Transl. Lung Cancer Res.</source><volume>7</volume><issue>3</issue><year>2018</year><fpage>220</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">30050761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2018.05.06</pub-id><pub-id pub-id-type="pmcid">PMC6037963</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Comparative proteomic profiling of human lung adenocarcinoma cells (CL 1-0) expressing miR-372</article-title><source>Electrophoresis</source><volume>33</volume><issue>4</issue><year>2012</year><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">22451061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/elps.201100329</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>R.</given-names></name><etal/></person-group><article-title>MicroRNA miR-372 enhances the malignant potential of lung cancer cells</article-title><source>J. Am. Coll. Surg.</source><volume>221</volume><issue>4</issue><year>2015</year><fpage>S151</fpage></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma</article-title><source>Cancer Med.</source><volume>6</volume><issue>6</issue><year>2017</year><fpage>1323</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">28440022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1026</pub-id><pub-id pub-id-type="pmcid">PMC5463061</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name></person-group><article-title>Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372</article-title><source>BMC Cancer</source><volume>18</volume><issue>1</issue><year>2018</year><fpage>1252</fpage><pub-id pub-id-type="pmid">30547768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-018-5175-y</pub-id><pub-id pub-id-type="pmcid">PMC6295097</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11017663"/></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Moradi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Emerging role of miR-372 and miR-101a in head and neck squamous cell carcinoma</article-title><source>Clin. Lab.</source><volume>66</volume><issue>4</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.7754/Clin.Lab.2019.190734</pub-id><pub-id pub-id-type="pmid">32255289</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name></person-group><article-title>Nasopharyngeal carcinoma: a review of current updates</article-title><source>Exp. Ther. Med.</source><volume>15</volume><issue>4</issue><year>2018</year><fpage>3687</fpage><lpage>3692</lpage><pub-id pub-id-type="pmid">29556258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2018.5878</pub-id><pub-id pub-id-type="pmcid">PMC5844099</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.P.</given-names></name><etal/></person-group><article-title>Nasopharyngeal carcinoma</article-title><source>Lancet</source><volume>394</volume><issue>10192</issue><year>2019</year><fpage>64</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">31178151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)30956-0</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>B.B.Y.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.T.C.</given-names></name></person-group><article-title>Investigational drugs for nasopharyngeal carcinoma</article-title><source>Expet Opin. Invest. Drugs</source><volume>26</volume><issue>6</issue><year>2017</year><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543784.2017.1324568</pub-id><pub-id pub-id-type="pmid">28446055</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L.Q.</given-names></name><etal/></person-group><article-title>Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma</article-title><source>J. Natl. Cancer Inst.</source><volume>108</volume><issue>1</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv291</pub-id><pub-id pub-id-type="pmid">26467665</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>D.T.</given-names></name><etal/></person-group><article-title>Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma</article-title><source>Cancer</source><volume>98</volume><issue>1</issue><year>2003</year><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12833458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.11485</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity</article-title><source>Carcinogenesis</source><volume>33</volume><issue>11</issue><year>2012</year><fpage>2220</fpage><lpage>2227</lpage><pub-id pub-id-type="pmid">22798379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgs235</pub-id><pub-id pub-id-type="pmcid">PMC3483015</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>S.Y.</given-names></name></person-group><article-title>Elucidating the roles of miR-372 in cell proliferation and apoptosis of nasopharyngeal carcinoma TW01 cells</article-title><source>Exp. Oncol.</source><volume>36</volume><issue>3</issue><year>2014</year><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">25265349</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MicroRNA-372 enhances radiosensitivity while inhibiting cell invasion and metastasis in nasopharyngeal carcinoma through activating the PBK-dependent p53 signaling pathway</article-title><source>Cancer Med.</source><volume>8</volume><issue>2</issue><year>2019</year><fpage>712</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">30656832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1924</pub-id><pub-id pub-id-type="pmcid">PMC6382924</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>McGlynn</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>London</surname><given-names>W.T.</given-names></name></person-group><article-title>Epidemiology and natural history of hepatocellular carcinoma</article-title><source>Best Pract. Res. Clin. Gastroenterol.</source><volume>19</volume><issue>1</issue><year>2005</year><fpage>3</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15757802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpg.2004.10.004</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Goodarzi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Global incidence and mortality of liver cancers and its relationship with the human development index (HDI): an ecology study in 2018</article-title><source>World Cancer Res J</source><volume>6</volume><year>2019</year><fpage>12</fpage></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma</article-title><source>BMC Cancer</source><volume>15</volume><year>2015</year><fpage>182</fpage><pub-id pub-id-type="pmid">25880458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-015-1214-0</pub-id><pub-id pub-id-type="pmcid">PMC4379970</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>MicroRNA-372-3p predicts response of TACE patients treated with doxorubicin and enhances chemosensitivity in hepatocellular carcinoma</article-title><source>Anti Cancer Agents Med. Chem.</source><volume>21</volume><issue>2</issue><year>2021</year><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520620666200516145830</pub-id><pub-id pub-id-type="pmid">32416702</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>lncRNA OSER1-AS1 acts as a ceRNA to promote tumorigenesis in hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>521</volume><issue>1</issue><year>2020</year><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">31635804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.10.105</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Shaker</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Long non-coding HULC and miRNA-372 as diagnostic biomarkers in hepatocellular carcinoma</article-title><source>Rep. Biochem. Mol. Biol.</source><volume>9</volume><issue>2</issue><year>2020</year><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">33178874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.29252/rbmb.9.2.230</pub-id><pub-id pub-id-type="pmcid">PMC7603263</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p</article-title><source>Cancer Cell Int.</source><volume>19</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">31413665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-019-0926-7</pub-id><pub-id pub-id-type="pmcid">PMC6688277</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11490101"/></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.J.</given-names></name></person-group><article-title>MicroRNA-16 suppressed the invasion and migration of osteosarcoma by directly inhibiting RAB23</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>22</volume><issue>9</issue><year>2018</year><fpage>2598</fpage><lpage>2605</lpage><pub-id pub-id-type="pmid">29771408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201805_14953</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer</article-title><source>Nucleic Acids Res.</source><volume>38</volume><issue>16</issue><year>2010</year><fpage>5366</fpage><lpage>5383</lpage><pub-id pub-id-type="pmid">20423907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkq285</pub-id><pub-id pub-id-type="pmcid">PMC2938198</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372</article-title><source>Oncotarget</source><volume>8</volume><issue>21</issue><year>2017</year><fpage>34429</fpage><lpage>34441</lpage><pub-id pub-id-type="pmid">28415780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.16260</pub-id><pub-id pub-id-type="pmcid">PMC5470980</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis</article-title><source>BMC Cancer</source><volume>14</volume><year>2014</year><fpage>107</fpage><pub-id pub-id-type="pmid">24552534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2407-14-107</pub-id><pub-id pub-id-type="pmcid">PMC4016509</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy</article-title><source>Mol. Ther. Nucleic Acids</source><volume>24</volume><year>2021</year><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">33868788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2021.02.006</pub-id><pub-id pub-id-type="pmcid">PMC8040129</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>MicroRNAs and head and neck cancer: reviewing the first decade of research</article-title><source>Eur. J. Cancer</source><volume>50</volume><issue>15</issue><year>2014</year><fpage>2619</fpage><lpage>2635</lpage><pub-id pub-id-type="pmid">25103455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2014.07.012</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>miR-372 enhances tumorigenesis and drug resistance in oral carcinoma by targeting ZBTB7A transcription factor</article-title><source>Cancer Res.</source><volume>78</volume><issue>13</issue><year>2018</year></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>The miR-372-ZBTB7A oncogenic Axis suppresses TRAIL-R2 associated drug sensitivity in oral carcinoma</article-title><source>Front. Oncol.</source><volume>10</volume><year>2020</year><fpage>47</fpage><pub-id pub-id-type="pmid">32083004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.00047</pub-id><pub-id pub-id-type="pmcid">PMC7005910</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>Hypoxia-induced miR-372 targets p62 to affect the progression of oral carcinoma</article-title><source>Cancer Res.</source><volume>74</volume><issue>19</issue><year>2014</year></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas</article-title><source>Laryngoscope</source><volume>125</volume><issue>11</issue><year>2015</year><fpage>E365</fpage><lpage>E370</lpage><pub-id pub-id-type="pmid">26152520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.25464</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Upregulation of microRNA-372 &amp; 373 associates with cervical lymph node metastasis and poor prognosis of oral carcinomas</article-title><source>Cancer Res.</source><volume>74</volume><issue>19</issue><year>2014</year></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MEHP promotes the proliferation of oral cancer cells via down regulation of miR-27b-5p and miR-372-5p</article-title><source>Toxicol. Vitro</source><volume>58</volume><year>2019</year><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tiv.2019.03.014</pub-id><pub-id pub-id-type="pmid">30858031</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Global burden of 5 major types of gastrointestinal cancer</article-title><source>Gastroenterology</source><volume>159</volume><issue>1</issue><year>2020</year><fpage>335</fpage><lpage>349.e15</lpage><pub-id pub-id-type="pmid">32247694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.02.068</pub-id><pub-id pub-id-type="pmcid">PMC8630546</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Wroblewski</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Peek</surname><given-names>R.M.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Helicobacter pylori, cancer, and the gastric microbiota</article-title><source>Adv. Exp. Med. Biol.</source><volume>908</volume><year>2016</year><fpage>393</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">27573782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-41388-4_19</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Lyons</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Gastric cancer: epidemiology, biology, and prevention: a mini review</article-title><source>Eur. J. Cancer Prev.</source><volume>28</volume><issue>5</issue><year>2019</year><fpage>397</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">31386635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000480</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Volinia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A microRNA expression signature of human solid tumors defines cancer gene targets</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>103</volume><issue>7</issue><year>2006</year><fpage>2257</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">16461460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0510565103</pub-id><pub-id pub-id-type="pmcid">PMC1413718</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Necula</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Recent advances in gastric cancer early diagnosis</article-title><source>World J. Gastroenterol.</source><volume>25</volume><issue>17</issue><year>2019</year><fpage>2029</fpage><lpage>2044</lpage><pub-id pub-id-type="pmid">31114131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v25.i17.2029</pub-id><pub-id pub-id-type="pmcid">PMC6506585</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2</article-title><source>Mol. Cell.</source><volume>28</volume><issue>6</issue><year>2009</year><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10059-009-0158-0</pub-id><pub-id pub-id-type="pmid">19937137</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mozdarani</surname><given-names>H.</given-names></name></person-group><article-title>The Effect of miR-372 on genome instability in MKN-45 cell line</article-title><comment>M.J.J.o.I.M.S. Soleimani</comment><source>J. Isfahan Med. School</source><volume>32</volume><issue>311</issue><year>2015</year></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><etal/></person-group><article-title>microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NF&#954;B signaling in human gastric carcinoma cells</article-title><source>Int. J. Oncol.</source><volume>42</volume><issue>2</issue><year>2013</year><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">23242208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2012.1737</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Staedel</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Inhibition of gastric tumor cell growth using seed-targeting LNA as specific, long-lasting MicroRNA inhibitors</article-title><source>Mol. Ther. Nucleic Acids</source><volume>4</volume><issue>7</issue><year>2015</year><fpage>e246</fpage><pub-id pub-id-type="pmid">26151747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtna.2015.18</pub-id><pub-id pub-id-type="pmcid">PMC4561653</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Belair</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Helicobacter pylori interferes with an embryonic stem cell micro RNA cluster to block cell cycle progression</article-title><source>Silence</source><volume>2</volume><issue>1</issue><year>2011</year><fpage>7</fpage><pub-id pub-id-type="pmid">22027184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1758-907X-2-7</pub-id><pub-id pub-id-type="pmcid">PMC3212895</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Vo</surname><given-names>D.D.</given-names></name><etal/></person-group><article-title>Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules</article-title><source>ACS Chem. Biol.</source><volume>9</volume><issue>3</issue><year>2014</year><fpage>711</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">24359019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cb400668h</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Cort&#233;</surname><given-names>H.</given-names></name><etal/></person-group><article-title>MicroRNA and colorectal cancer</article-title><source>Dig. Liver Dis.</source><volume>44</volume><issue>3</issue><year>2012</year><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">22105087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2011.10.010</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Schetter</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Okayama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>C.C.</given-names></name></person-group><article-title>The role of microRNAs in colorectal cancer</article-title><source>Cancer J.</source><volume>18</volume><issue>3</issue><year>2012</year><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">22647361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PPO.0b013e318258b78f</pub-id><pub-id pub-id-type="pmcid">PMC3397427</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>MiR-372-3p promotes tumor progression by targeting LATS2 in colorectal cancer</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>23</volume><issue>19</issue><year>2019</year><fpage>8332</fpage><lpage>8344</lpage><pub-id pub-id-type="pmid">31646563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201910_19144</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer</article-title><source>Anti Cancer Agents Med. Chem.</source><volume>16</volume><issue>4</issue><year>2016</year><fpage>424</fpage><lpage>431</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520615666150716110406</pub-id><pub-id pub-id-type="pmid">26179262</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy</article-title><source>Anti Cancer Drugs</source><volume>25</volume><issue>3</issue><year>2014</year><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">24304648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000000049</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Ragusa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors</article-title><source>J. Mol. Med. (Berl.)</source><volume>90</volume><issue>12</issue><year>2012</year><fpage>1421</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">22660396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-012-0918-8</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.Q.</given-names></name><etal/></person-group><article-title>miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways</article-title><source>Mol. Oncol.</source><volume>12</volume><issue>11</issue><year>2018</year><fpage>1949</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">30171794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1878-0261.12376</pub-id><pub-id pub-id-type="pmcid">PMC6210048</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Alkhayyat</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Epidemiology of gallbladder cancer in the Unites States: a population-based study</article-title><source>Chin. Clin. Oncol.</source><volume>10</volume><issue>3</issue><year>2021</year><fpage>25</fpage><pub-id pub-id-type="pmid">33615799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/cco-20-230</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Valle</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Biliary tract cancer</article-title><source>Lancet</source><volume>397</volume><issue>10272</issue><year>2021</year><fpage>428</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">33516341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00153-7</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Decreased expression of hsa-miR-372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1</article-title><source>Mol. Med. Rep.</source><volume>16</volume><issue>5</issue><year>2017</year><fpage>7848</fpage><lpage>7854</lpage><pub-id pub-id-type="pmid">28944858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2017.7520</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Mizrahi</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Pancreatic cancer</article-title><source>Lancet</source><volume>395</volume><issue>10242</issue><year>2020</year><fpage>2008</fpage><lpage>2020</lpage><pub-id pub-id-type="pmid">32593337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30974-0</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Worldwide burden of, risk factors for, and trends in pancreatic cancer</article-title><source>Gastroenterology</source><volume>160</volume><issue>3</issue><year>2021</year><fpage>744</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">33058868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.10.007</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells</article-title><source>Cancer Sci.</source><volume>108</volume><issue>9</issue><year>2017</year><fpage>1811</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">28677209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.13315</pub-id><pub-id pub-id-type="pmcid">PMC5581518</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>MicroRNA alterations of pancreatic intraepithelial neoplasias</article-title><source>Clin. Cancer Res.</source><volume>18</volume><issue>4</issue><year>2012</year><fpage>981</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">22114139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-11-2347</pub-id><pub-id pub-id-type="pmcid">PMC3288338</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>DeSantis</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Breast cancer statistics</article-title><source>CA A Cancer J. Clin.</source><volume>69</volume><issue>6</issue><year>2019</year><fpage>438</fpage><lpage>451</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21583</pub-id><pub-id pub-id-type="pmid">31577379</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA A Cancer J. Clin.</source><volume>68</volume><issue>6</issue><year>2018</year><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA A Cancer J. Clin.</source><volume>70</volume><issue>1</issue><year>2020</year><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21590</pub-id><pub-id pub-id-type="pmid">31912902</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Momenimovahed</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Salehiniya</surname><given-names>H.</given-names></name></person-group><article-title>Epidemiological characteristics of and risk factors for breast cancer in the world</article-title><source>Breast Cancer</source><volume>11</volume><year>2019</year><fpage>151</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">31040712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/BCTT.S176070</pub-id><pub-id pub-id-type="pmcid">PMC6462164</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>W&#246;ckel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, december 2017) - Part 1 with recommendations for the screening, diagnosis and therapy of breast cancer</article-title><source>Geburtshilfe Frauenheilkd</source><volume>78</volume><issue>10</issue><year>2018</year><fpage>927</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">30369626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-0646-4522</pub-id><pub-id pub-id-type="pmcid">PMC6202580</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Waks</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>E.P.</given-names></name></person-group><article-title>Breast cancer treatment: a review</article-title><source>JAMA</source><volume>321</volume><issue>3</issue><year>2019</year><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">30667505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19323</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>The emerging role of MicroRNAs in breast cancer</article-title><source>J. Oncol.</source><volume>2020</volume><year>2020</year><fpage>9160905</fpage><pub-id pub-id-type="pmid">32714393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/9160905</pub-id><pub-id pub-id-type="pmcid">PMC7354667</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>miR-372 promotes breast cancer cell proliferation by directly targeting LATS2</article-title><source>Exp. Ther. Med.</source><volume>15</volume><issue>3</issue><year>2018</year><fpage>2812</fpage><lpage>2817</lpage><pub-id pub-id-type="pmid">29456685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2018.5761</pub-id><pub-id pub-id-type="pmcid">PMC5795589</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>MicroRNA-372-3p promotes the epithelial-mesenchymal transition in breast carcinoma by activating the Wnt pathway</article-title><source>J buon</source><volume>23</volume><issue>5</issue><year>2018</year><fpage>1309</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">30570852</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Current and future therapeutic approaches for osteosarcoma</article-title><source>Expert Rev. Anticancer Ther.</source><volume>18</volume><issue>1</issue><year>2018</year><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">29210294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737140.2018.1413939</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Eaton</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Osteosarcoma</article-title><source>Pediatr. Blood Cancer</source><volume>68</volume><issue>2</issue><year>2021</year><object-id pub-id-type="publisher-id">e28352</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.28771</pub-id><pub-id pub-id-type="pmcid">PMC9137401</pub-id><pub-id pub-id-type="pmid">33063919</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Sadykova</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Epidemiology and risk factors of osteosarcoma</article-title><source>Cancer Invest.</source><volume>38</volume><issue>5</issue><year>2020</year><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32400205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07357907.2020.1768401</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Osteosarcoma: a review of current and future therapeutic approaches</article-title><source>Biomed. Eng. Online</source><volume>20</volume><issue>1</issue><year>2021</year><fpage>24</fpage><pub-id pub-id-type="pmid">33653371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12938-021-00860-0</pub-id><pub-id pub-id-type="pmcid">PMC7923306</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Czarnecka</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Molecular biology of osteosarcoma</article-title><source>Cancers</source><volume>12</volume><issue>8</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12082130</pub-id><pub-id pub-id-type="pmcid">PMC7463657</pub-id><pub-id pub-id-type="pmid">32751922</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Osteosarcoma and metastasis</article-title><source>Front. Oncol.</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">780264</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.780264</pub-id><pub-id pub-id-type="pmcid">PMC8702962</pub-id><pub-id pub-id-type="pmid">34956899</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>An update on the roles of circular RNAs in osteosarcoma</article-title><source>Cell Prolif.</source><volume>54</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">e12936</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cpr.12936</pub-id><pub-id pub-id-type="pmcid">PMC7791175</pub-id><pub-id pub-id-type="pmid">33103338</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.T.</given-names></name></person-group><article-title>MiR-372-3p inhibits the growth and metastasis of osteosarcoma cells by targeting FXYD6</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>22</volume><issue>1</issue><year>2018</year><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">29364472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201801_14101</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>CircRNA Circ_0001721 promotes the progression of osteosarcoma through miR-372-3p/MAPK7 Axis</article-title><source>Cancer Manag. Res.</source><volume>12</volume><year>2020</year><fpage>8287</fpage><lpage>8302</lpage><pub-id pub-id-type="pmid">32982424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CMAR.S244527</pub-id><pub-id pub-id-type="pmcid">PMC7498501</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis</article-title><source>Mol. Med.</source><volume>26</volume><issue>1</issue><year>2020</year><fpage>26</fpage><pub-id pub-id-type="pmid">32188407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-020-00155-5</pub-id><pub-id pub-id-type="pmcid">PMC7081592</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Nazarizadeh</surname><given-names>A.</given-names></name><etal/></person-group><article-title>MicroRNA-154: a novel candidate for diagnosis and therapy of human cancers</article-title><source>OncoTargets Ther.</source><volume>13</volume><year>2020</year><fpage>6603</fpage><lpage>6615</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S249268</pub-id><pub-id pub-id-type="pmcid">PMC7354082</pub-id><pub-id pub-id-type="pmid">32753896</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Fankhauser</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Mostafid</surname><given-names>H.</given-names></name></person-group><article-title>Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle</article-title><source>Curr. Opin. Urol.</source><volume>28</volume><issue>1</issue><year>2018</year><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">29211694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOU.0000000000000452</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Saginala</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Epidemiology of bladder cancer</article-title><source>Med. Sci.</source><volume>8</volume><issue>1</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medsci8010015</pub-id><pub-id pub-id-type="pmcid">PMC7151633</pub-id><pub-id pub-id-type="pmid">32183076</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>V.K.</given-names></name><etal/></person-group><article-title>Imaging and management of bladder cancer</article-title><source>Cancers</source><volume>13</volume><issue>6</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13061396</pub-id><pub-id pub-id-type="pmcid">PMC8003397</pub-id><pub-id pub-id-type="pmid">33808614</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Frontiers in bladder cancer genomic research</article-title><source>Front. Oncol.</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">670729</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.670729</pub-id><pub-id pub-id-type="pmcid">PMC8173177</pub-id><pub-id pub-id-type="pmid">34094968</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer</article-title><source>Oncogene</source><volume>39</volume><issue>17</issue><year>2020</year><fpage>3588</fpage><lpage>3603</lpage><pub-id pub-id-type="pmid">32127645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-020-1236-1</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Bedell</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Cervical cancer screening: past, present, and future</article-title><source>Sex Med. Rev.</source><volume>8</volume><issue>1</issue><year>2020</year><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">31791846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sxmr.2019.09.005</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Eun</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>R.B.</given-names></name></person-group><article-title>Screening for cervical cancer</article-title><source>Med. Clin.</source><volume>104</volume><issue>6</issue><year>2020</year><fpage>1063</fpage><lpage>1078</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2020.08.006</pub-id><pub-id pub-id-type="pmcid">PMC8881993</pub-id><pub-id pub-id-type="pmid">33099451</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Revathidevi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>APOBEC: a molecular driver in cervical cancer pathogenesis</article-title><source>Cancer Lett.</source><volume>496</volume><year>2021</year><fpage>104</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">33038491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2020.10.004</pub-id><pub-id pub-id-type="pmcid">PMC7539941</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>R.Q.</given-names></name><etal/></person-group><article-title>MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and Cyclin A1 in human cervical cancer, which may contribute to tumorigenesis</article-title><source>J. Biol. Chem.</source><volume>286</volume><issue>29</issue><year>2011</year><fpage>25556</fpage><lpage>25563</lpage><pub-id pub-id-type="pmid">21646351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.221564</pub-id><pub-id pub-id-type="pmcid">PMC3138314</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Di Tucci</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Immunotherapy in endometrial cancer: new scenarios on the horizon</article-title><source>J Gynecol Oncol</source><volume>30</volume><issue>3</issue><year>2019</year><fpage>e46</fpage><pub-id pub-id-type="pmid">30887763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3802/jgo.2019.30.e46</pub-id><pub-id pub-id-type="pmcid">PMC6424849</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Raglan</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Risk factors for endometrial cancer: an umbrella review of the literature</article-title><source>Int. J. Cancer</source><volume>145</volume><issue>7</issue><year>2019</year><fpage>1719</fpage><lpage>1730</lpage><pub-id pub-id-type="pmid">30387875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31961</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>M.A.</given-names></name></person-group><article-title>Endometrial cancer: is this a new disease?</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><volume>37</volume><year>2017</year><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">28561715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_175666</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Urick</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>D.W.</given-names></name></person-group><article-title>Clinical actionability of molecular targets in endometrial cancer</article-title><source>Nat. Rev. Cancer</source><volume>19</volume><issue>9</issue><year>2019</year><fpage>510</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">31388127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0177-x</pub-id><pub-id pub-id-type="pmcid">PMC7446243</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC)</article-title><source>Oncotarget</source><volume>7</volume><issue>6</issue><year>2016</year><fpage>6649</fpage><lpage>6664</lpage><pub-id pub-id-type="pmid">26673619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6544</pub-id><pub-id pub-id-type="pmcid">PMC4872740</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Momenimovahed</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Ovarian cancer in the world: epidemiology and risk factors</article-title><source>Int J Womens Health</source><volume>11</volume><year>2019</year><fpage>287</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">31118829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJWH.S197604</pub-id><pub-id pub-id-type="pmcid">PMC6500433</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Torre</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Ovarian cancer statistics</article-title><source>CA A Cancer J. Clin.</source><volume>68</volume><issue>4</issue><year>2018</year><fpage>284</fpage><lpage>296</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21456</pub-id><pub-id pub-id-type="pmcid">PMC6621554</pub-id><pub-id pub-id-type="pmid">29809280</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The role of miR-372 in ovarian carcinoma cell proliferation</article-title><source>Gene</source><volume>624</volume><year>2017</year><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28456593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2017.04.043</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Shingarev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>E.A.</given-names></name></person-group><article-title>Renal cell carcinoma: new insights and challenges for a clinician scientist</article-title><source>Am. J. Physiol. Ren. Physiol.</source><volume>313</volume><issue>2</issue><year>2017</year><fpage>F145</fpage><lpage>f154</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00480.2016</pub-id><pub-id pub-id-type="pmcid">PMC5582896</pub-id><pub-id pub-id-type="pmid">28381462</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Petejova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martinek</surname><given-names>A.</given-names></name></person-group><article-title>Renal cell carcinoma: review of etiology, pathophysiology and risk factors</article-title><source>Biomed Pap Med. Fac. Univ. Palacky Olomouc Czech Repub</source><volume>160</volume><issue>2</issue><year>2016</year><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">26558360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5507/bp.2015.050</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Perazella</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dreicer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosner</surname><given-names>M.H.</given-names></name></person-group><article-title>Renal cell carcinoma for the nephrologist</article-title><source>Kidney Int.</source><volume>94</volume><issue>3</issue><year>2018</year><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">29661544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2018.01.023</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The emerging role of small non-coding RNA in renal cell carcinoma</article-title><source>Transl. Oncol.</source><volume>14</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">100974</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2020.100974</pub-id><pub-id pub-id-type="pmcid">PMC7719974</pub-id><pub-id pub-id-type="pmid">33395751</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma</article-title><source>Cell Prolif.</source><volume>48</volume><issue>5</issue><year>2015</year><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">26332146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cpr.12207</pub-id><pub-id pub-id-type="pmcid">PMC6496015</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MicroRNA-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting ATAD2 in renal cell carcinoma</article-title><source>Oncol. Lett.</source><volume>17</volume><issue>2</issue><year>2019</year><fpage>2400</fpage><lpage>2408</lpage><pub-id pub-id-type="pmid">30719113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2018.9871</pub-id><pub-id pub-id-type="pmcid">PMC6350190</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Pernar</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>The epidemiology of prostate cancer</article-title><source>Cold Spring Harb Perspect Med</source><volume>8</volume><issue>12</issue><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a030361</pub-id><pub-id pub-id-type="pmcid">PMC6280714</pub-id><pub-id pub-id-type="pmid">29311132</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Merriel</surname><given-names>S.W.D.</given-names></name><name name-style="western"><surname>Funston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>W.</given-names></name></person-group><article-title>Prostate cancer in primary care</article-title><source>Adv. Ther.</source><volume>35</volume><issue>9</issue><year>2018</year><fpage>1285</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">30097885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-018-0766-1</pub-id><pub-id pub-id-type="pmcid">PMC6133140</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Humphrey</surname><given-names>P.A.</given-names></name></person-group><article-title>Histopathology of prostate cancer</article-title><source>Cold Spring Harb Perspect Med</source><volume>7</volume><issue>10</issue><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a030411</pub-id><pub-id pub-id-type="pmcid">PMC5629988</pub-id><pub-id pub-id-type="pmid">28389514</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Haffner</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Genomic and phenotypic heterogeneity in prostate cancer</article-title><source>Nat. Rev. Urol.</source><volume>18</volume><issue>2</issue><year>2021</year><fpage>79</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">33328650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41585-020-00400-w</pub-id><pub-id pub-id-type="pmcid">PMC7969494</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Genetics and biology of prostate cancer</article-title><source>Genes Dev.</source><volume>32</volume><issue>17&#8211;18</issue><year>2018</year><fpage>1105</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">30181359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.315739.118</pub-id><pub-id pub-id-type="pmcid">PMC6120714</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><etal/></person-group><article-title>microRNA-372 suppresses migration and invasion by targeting p65 in human prostate cancer cells</article-title><source>DNA Cell Biol.</source><volume>35</volume><issue>12</issue><year>2016</year><fpage>828</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">27673408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dna.2015.3186</pub-id><pub-id pub-id-type="pmcid">PMC5165676</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Repression of MicroRNA-372 by arsenic sulphide inhibits prostate cancer cell proliferation and migration through regulation of large tumour suppressor kinase 2</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><volume>120</volume><issue>3</issue><year>2017</year><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">27730751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.12687</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Singla</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genetics of testicular germ cell tumors</article-title><source>Curr. Opin. Urol.</source><volume>29</volume><issue>4</issue><year>2019</year><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">31045925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOU.0000000000000642</pub-id><pub-id pub-id-type="pmcid">PMC6659740</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Damjanov</surname><given-names>I.</given-names></name></person-group><article-title>Testicular germ cell tumors: serological and immunohistochemical diagnosis</article-title><source>Acta Med. Acad.</source><volume>50</volume><issue>1</issue><year>2021</year><fpage>58</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">34075764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5644/ama2006-124.326</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Mele</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huddart</surname><given-names>R.</given-names></name></person-group><article-title>Recent advances in testicular germ cell tumours</article-title><source>Fac. Rev.</source><volume>10</volume><year>2021</year><fpage>67</fpage><pub-id pub-id-type="pmid">34557871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12703/r/10-67</pub-id><pub-id pub-id-type="pmcid">PMC8441995</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Voorhoeve</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors</article-title><source>Adv. Exp. Med. Biol.</source><volume>604</volume><year>2007</year><fpage>17</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17695719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-0-387-69116-9_2</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><article-title>Abstracts of the 65th congress of the German society for urology. September 25-28, 2013. Dresden, Germany]</article-title><source>Urologe</source><volume>52</volume><issue>Suppl 1</issue><year>2013</year><fpage>10</fpage><lpage>151</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00120-013-3273-7</pub-id><pub-id pub-id-type="pmid">24013688</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Syring</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer</article-title><source>J. Urol.</source><volume>193</volume><issue>1</issue><year>2015</year><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">25046619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2014.07.010</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Iman</surname><given-names>M.</given-names></name><etal/></person-group><article-title>HOXB7 and hsa-miR-222 as the potential therapeutic candidates for metastatic colorectal cancer</article-title><source>Recent Pat. Anti-Cancer Drug Discov.</source><volume>11</volume><issue>4</issue><year>2016</year><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1574892811999160628114857</pub-id><pub-id pub-id-type="pmid">27855613</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology</article-title><source>ACS Nano</source><volume>9</volume><issue>10</issue><year>2015</year><fpage>9731</fpage><lpage>9740</lpage><pub-id pub-id-type="pmid">26387848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b02471</pub-id><pub-id pub-id-type="pmcid">PMC4723066</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.T.</given-names></name><etal/></person-group><article-title>Noncoding RNAs in cancer therapy resistance and targeted drug development</article-title><source>J. Hematol. Oncol.</source><volume>12</volume><issue>1</issue><year>2019</year><fpage>55</fpage><pub-id pub-id-type="pmid">31174564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-019-0748-z</pub-id><pub-id pub-id-type="pmcid">PMC6556047</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Ganju</surname><given-names>A.</given-names></name><etal/></person-group><article-title>miRNA nanotherapeutics for cancer</article-title><source>Drug Discov. Today</source><volume>22</volume><issue>2</issue><year>2017</year><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">27815139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2016.10.014</pub-id><pub-id pub-id-type="pmcid">PMC5309208</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Javanmardi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>miR-21, an oncogenic target miRNA for cancer therapy: molecular mechanisms and recent advancements in chemo and radio-resistance</article-title><source>Curr. Gene Ther.</source><volume>16</volume><issue>6</issue><year>2017</year><fpage>375</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">28042781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566523217666170102105119</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21</article-title><source>Mol. Ther.</source><volume>25</volume><issue>7</issue><year>2017</year><fpage>1544</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">28109960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2016.11.016</pub-id><pub-id pub-id-type="pmcid">PMC5498802</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Co&#8208;delivery of micro RNA&#8208;21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy</article-title><source>Cancer Sci.</source><volume>108</volume><issue>7</issue><year>2017</year><fpage>1493</fpage><lpage>1503</lpage><pub-id pub-id-type="pmid">28444967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.13267</pub-id><pub-id pub-id-type="pmcid">PMC5497927</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Jabbari</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Assessment of synergistic effect of combining hyperthermia with irradiation and calcium carbonate nanoparticles on proliferation of human breast adenocarcinoma cell line (MCF-7 cells)</article-title><source>Artif. Cells, Nanomed. Biotechnol.</source><volume>46</volume><issue>sup2</issue><year>2018</year><fpage>364</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">29616844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21691401.2018.1457537</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Comparative proteomic profiling of human lung adenocarcinoma cells (CL 1&#8211;0) expressing miR&#8208;372</article-title><source>Electrophoresis</source><volume>33</volume><issue>4</issue><year>2012</year><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">22451061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/elps.201100329</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name></person-group><article-title>Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372</article-title><source>BMC Cancer</source><volume>18</volume><issue>1</issue><year>2018</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30547768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-018-5175-y</pub-id><pub-id pub-id-type="pmcid">PMC6295097</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11017663"/></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>R.</given-names></name><etal/></person-group><article-title>MicroRNA miR-372 enhances the malignant potential of lung cancer cells</article-title><source>J. Am. Coll. Surg.</source><volume>221</volume><year>2015</year><fpage>S151</fpage></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>MiR&#8208;372&#8208;3p promotes cell growth and metastasis by targeting FGF 9 in lung squamous cell carcinoma</article-title><source>Cancer Med.</source><volume>6</volume><issue>6</issue><year>2017</year><fpage>1323</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">28440022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1026</pub-id><pub-id pub-id-type="pmcid">PMC5463061</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MicroRNA&#8208;372 enhances radiosensitivity while inhibiting cell invasion and metastasis in nasopharyngeal carcinoma through activating the PBK&#8208;dependent p53 signaling pathway</article-title><source>Cancer Med.</source><volume>8</volume><issue>2</issue><year>2019</year><fpage>712</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">30656832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1924</pub-id><pub-id pub-id-type="pmcid">PMC6382924</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>S.</given-names></name></person-group><article-title>Elucidating the roles of miR-372 in cell proliferation and apoptosis of nasopharyngeal carcinoma TW01 cells</article-title><source>Exp. Oncol.</source><volume>36</volume><issue>3</issue><year>2014</year><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">25265349</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer</article-title><source>Nucleic Acids Res.</source><volume>38</volume><issue>16</issue><year>2010</year><fpage>5366</fpage><lpage>5383</lpage><pub-id pub-id-type="pmid">20423907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkq285</pub-id><pub-id pub-id-type="pmcid">PMC2938198</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis</article-title><source>BMC Cancer</source><volume>14</volume><issue>1</issue><year>2014</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">24552534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2407-14-107</pub-id><pub-id pub-id-type="pmcid">PMC4016509</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>MiR-372-3p predicts response of TACE patients treated with doxorubicin and enhances chemosensitivity in hepatocellular carcinoma</article-title><source>Anti Cancer Agents Med. Chem.</source><volume>21</volume><issue>2</issue><year>2021</year><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520620666200516145830</pub-id><pub-id pub-id-type="pmid">32416702</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy</article-title><source>Mol. Ther. Nucleic Acids</source><volume>24</volume><year>2021</year><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">33868788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2021.02.006</pub-id><pub-id pub-id-type="pmcid">PMC8040129</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p</article-title><source>Cell Death Dis.</source><volume>11</volume><issue>10</issue><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">33082306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-03083-8</pub-id><pub-id pub-id-type="pmcid">PMC7575601</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>lncRNA OSER1-AS1 acts as a ceRNA to promote tumorigenesis in hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>521</volume><issue>1</issue><year>2020</year><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">31635804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.10.105</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>